,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,155,1,1,,68349,289,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
1,157,1,1,,68349,289,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
2,161,1,1,,68349,289,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
3,165,1,1,,68349,289,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
4,167,1,1,,68349,289,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
5,175,1,1,,68349,289,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
6,330,1,1,,68349,289,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
7,357,2,1,,11111004,289,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
8,410,1,5,,11111004,289,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
9,411,2,1,,11111004,289,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
10,421,1,3,,17389988,289,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
11,422,1,5,,17404843,289,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
12,426,1,2,,17389988,289,Active,,,,,Cell Viability - Jurkat,Confirmatory,,
13,427,1,1,,17389988,289,Active,,,,,Cell Viability - Hek293,Confirmatory,,
14,429,1,5,,17404843,289,Active,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
15,429,1,5,,17404843,289,Active,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
16,433,1,1,,17389988,289,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
17,434,1,2,,17389988,289,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
18,435,1,2,,17389988,289,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
19,436,2,1,,17404843,289,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
20,444,1,1,,11111004,289,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
21,445,3,1,,11111004,289,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
22,445,3,1,,17389988,289,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
23,446,1,1,,11111004,289,Inconclusive,,,,,Stat Signaling Pathway,Confirmatory,,
24,447,1,1,,11111004,289,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
25,448,1,2,,11111004,289,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
26,450,1,2,,11111004,289,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
27,451,1,2,,11111004,289,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
28,526,1,1,,11111004,289,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
29,530,1,1,,11111004,289,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
30,530,1,1,,17389988,289,Inconclusive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
31,540,1,1,,17389988,289,Inconclusive,,,,,Cell Viability - N2a,Confirmatory,,
32,541,1,1,,17389988,289,Active,,,,,Cell Viability - NIH 3T3,Confirmatory,,
33,542,1,1,,17389988,289,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
34,543,1,1,,17389988,289,Inconclusive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
35,544,2,1,,17389988,289,Active,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
36,545,1,1,,17389988,289,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
37,546,1,1,,17389988,289,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
38,547,1,4,,17404843,289,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
39,584,1,3,,11111004,289,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
40,584,1,3,,17389988,289,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
41,585,1,4,,11111004,289,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
42,585,1,4,,17389988,289,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
43,587,1,5,,11111004,289,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
44,588,1,4,,11111004,289,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
45,589,1,3,,11111004,289,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
46,590,1,3,,11111004,289,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
47,591,1,4,,11111004,289,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
48,592,1,6,,11111004,289,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
49,593,1,4,,11111004,289,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
50,594,1,4,,11111004,289,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
51,595,1,3,,11111004,289,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
52,595,1,3,,17389988,289,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
53,596,1,2,,11111004,289,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
54,596,1,2,,17389988,289,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
55,597,1,3,,11111004,289,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
56,603,1,2,,11111004,289,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
57,603,1,2,,17389988,289,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
58,605,1,2,,11111004,289,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
59,605,1,2,,17389988,289,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
60,607,1,3,,11111004,289,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
61,654,1,1,,17389988,289,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
62,655,1,1,,17389988,289,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
63,656,1,1,,17389988,289,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
64,657,1,1,,17389988,289,Inconclusive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
65,658,1,1,,17389988,289,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
66,659,1,1,,17389988,289,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
67,660,1,1,,17389988,289,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
68,661,1,1,,17389988,289,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
69,662,1,1,,11111004,289,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
70,662,1,1,,17389988,289,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
71,663,1,1,,17389988,289,Inconclusive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
72,664,1,1,,17389988,289,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
73,665,1,1,,17389988,289,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
74,666,1,1,,17389988,289,Inconclusive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
75,667,1,1,,17389988,289,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
76,694,1,1,,17404843,289,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
77,732,1,2,,17404843,289,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
78,875,1,2,,17389988,289,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
79,879,1,2,,17389988,289,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
80,879,1,2,,17389988,289,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
81,880,2,1,,17389988,289,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
82,880,2,1,,17389988,289,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
83,880,2,1,,50105556,289,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
84,880,2,1,,50105556,289,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
85,881,2,2,,17389988,289,Inconclusive,317373425.0,247.0,12.5893,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
86,883,1,3,,11111004,289,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
87,884,1,2,,17389988,289,Inconclusive,13435386.0,1576.0,10.0,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
88,885,1,2,,17389988,289,Inactive,13435386.0,1576.0,10.0,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
89,886,1,2,,11111004,289,Active,122921310.0,,1.5849,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
90,886,1,2,,11111004,289,Active,122921311.0,,1.5849,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
91,886,1,2,,17389988,289,Active,122921310.0,,2.5119,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
92,886,1,2,,17389988,289,Active,122921311.0,,2.5119,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
93,887,1,2,,17389988,289,Active,1832253.0,246.0,15.8489,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
94,889,1,3,,17389988,289,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
95,891,1,2,,11111004,289,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
96,892,1,2,,17389988,289,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
97,893,1,2,,17389988,289,Inconclusive,122921310.0,,25.1189,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
98,893,1,2,,17389988,289,Inconclusive,122921311.0,,25.1189,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
99,894,2,1,,17389988,289,Active,31542939.0,3248.0,11.2202,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
100,894,2,1,,50105556,289,Active,31542939.0,3248.0,17.7828,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
101,895,1,2,,17389988,289,Inconclusive,21620132.0,4790.0,2.2387,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
102,899,1,2,,11111004,289,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
103,900,1,3,,17389988,289,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
104,901,1,2,,17389988,289,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
105,902,1,2,,17389988,289,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
106,912,1,2,,11111004,289,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
107,912,1,2,,17389988,289,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
108,914,1,3,,11111004,289,Inconclusive,32879895.0,3091.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
109,915,1,3,,11111004,289,Active,32879895.0,3091.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
110,917,1,3,,17389988,289,Inconclusive,120660324.0,7066.0,5.0119,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
111,918,1,3,,17389988,289,Inconclusive,120660324.0,7066.0,5.0119,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
112,921,1,2,,17389988,289,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-001,Confirmatory,,
113,923,1,2,,17389988,289,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
114,924,1,2,,17389988,289,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
115,925,1,2,,11111004,289,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
116,925,1,2,,17389988,289,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
117,926,1,2,,11111004,289,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
118,926,1,2,,17389988,289,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
119,927,1,3,,17389988,289,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
120,928,1,2,,17389988,289,Inconclusive,21620132.0,4790.0,2.2387,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
121,938,1,2,,11111004,289,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
122,938,1,2,,17389988,289,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
123,940,1,2,,17404843,289,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
124,943,1,2,,17389988,289,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
125,944,1,2,,17389988,289,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
126,945,1,4,,17389988,289,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
127,946,1,2,,17389988,289,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
128,947,1,2,,17389988,289,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
129,948,1,2,,17389988,289,Inconclusive,,,25.1189,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
130,954,1,2,,17389988,289,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
131,955,1,2,,17389988,289,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
132,957,1,2,,17389988,289,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
133,958,1,2,,17389988,289,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
134,959,1,4,,17389988,289,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
135,960,1,2,,17389988,289,Active,,,19.9526,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
136,961,1,2,,17389988,289,Active,,,12.5893,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
137,962,1,2,,17389988,289,Inconclusive,,,6.3096,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
138,963,1,2,,17389988,289,Inconclusive,,,10.0,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
139,964,1,2,,17389988,289,Active,,,7.9433,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
140,965,1,2,,17389988,289,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
141,966,1,2,,17389988,289,Inconclusive,,,12.5893,Potency,Cell Viability - LYMP2-004,Confirmatory,,
142,967,1,2,,17389988,289,Inconclusive,,,10.0,Potency,Cell Viability - LYMP2-005,Confirmatory,,
143,968,1,2,,17389988,289,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-009,Confirmatory,,
144,969,1,2,,17389988,289,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-011,Confirmatory,,
145,970,1,2,,17389988,289,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-013,Confirmatory,,
146,971,1,2,,17389988,289,Inconclusive,,,12.5893,Potency,Cell Viability - LYMP2-015,Confirmatory,,
147,972,1,2,,17389988,289,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
148,973,1,2,,17389988,289,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
149,974,1,2,,17389988,289,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-021,Confirmatory,,
150,975,1,2,,17389988,289,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
151,976,1,2,,17389988,289,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
152,977,1,2,,17389988,289,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-002,Confirmatory,,
153,978,1,2,,17389988,289,Inconclusive,,,19.9526,Potency,Cell Viability - LYMP2-006,Confirmatory,,
154,979,1,2,,17389988,289,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
155,980,1,2,,17389988,289,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
156,981,1,2,,17389988,289,Active,,,19.9526,Potency,Cell Viability - LYMP2-010,Confirmatory,,
157,982,1,2,,17389988,289,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-012,Confirmatory,,
158,983,1,2,,17389988,289,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-014,Confirmatory,,
159,984,1,2,,17389988,289,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
160,985,1,2,,17389988,289,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-018,Confirmatory,,
161,986,1,2,,17389988,289,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-020,Confirmatory,,
162,987,1,2,,17389988,289,Inconclusive,,,15.8489,Potency,Cell Viability - LYMP2-022,Confirmatory,,
163,988,1,2,,17389988,289,Inconclusive,,,31.6228,Potency,Cell Viability - LYMP2-024,Confirmatory,,
164,989,1,2,,17389988,289,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-026,Confirmatory,,
165,992,1,3,,17389988,289,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
166,993,1,2,,17389988,289,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
167,994,1,2,,17389988,289,Active,,,15.8489,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
168,995,1,2,,17389988,289,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
169,997,1,2,,17389988,289,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
170,998,1,2,,17389988,289,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
171,1030,2,1,,17389988,289,Active,30582681.0,216.0,17.7828,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
172,1030,2,1,,50105556,289,Active,30582681.0,216.0,14.1254,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
173,1188,1,2,,48415156,289,Active,,,,,DSSTox (EPAFHM) EPA Fathead Minnow Acute Toxicity,Other,,
174,1189,1,5,,48413390,289,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
175,1194,1,3,,48413390,289,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
176,1199,1,3,,48413390,289,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
177,1205,1,4,,48413390,289,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
178,1208,1,3,,48413390,289,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
179,1379,1,2,,50105556,289,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
180,1422,1,1,,17404843,289,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
181,1452,1,1,,17389988,289,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
182,1454,1,1,,50105556,289,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
183,1457,1,1,,17389988,289,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
184,1457,1,1,,50105556,289,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
185,1458,1,1,,17389988,289,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
186,1458,1,1,,50105556,289,Inconclusive,10937869.0,6607.0,12.5893,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
187,1459,1,1,,50105556,289,Inconclusive,27436948.0,4000.0,35.4813,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
188,1460,1,3,,50105556,289,Inconclusive,92096784.0,4137.0,14.1254,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
189,1461,1,2,,50105556,289,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
190,1463,1,1,,50105556,289,Inconclusive,,,25.1189,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
191,1467,1,3,,50105556,289,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
192,1468,1,1,,50105556,289,Inconclusive,92096784.0,4137.0,1.4125,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
193,1469,1,1,,17389988,289,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
194,1469,1,1,,50105556,289,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
195,1471,2,1,,11111004,289,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
196,1471,2,1,,17389988,289,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
197,1476,2,1,,17389988,289,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
198,1476,2,1,,50105556,289,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
199,1477,1,1,,17389988,289,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
200,1477,1,1,,50105556,289,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
201,1478,2,1,,17389988,289,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
202,1478,2,1,,50105556,289,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
203,1479,1,2,,17389988,289,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
204,1479,1,2,,50105556,289,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
205,1487,1,1,,50105556,289,Inconclusive,27436948.0,4000.0,11.2202,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
206,1519,1,3,,50105556,289,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
207,1705,1,2,,50105556,289,Active,6980812.0,,35.4813,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
208,1707,1,3,,50105556,289,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
209,1708,1,3,,50105556,289,Inactive,405898.0,,19.9526,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
210,1766,1,1,,50105556,289,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
211,1766,1,1,,50105556,289,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
212,1768,1,1,,50105556,289,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
213,1768,1,1,,50105556,289,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
214,1815,1,1,,50105556,289,Inconclusive,,,12.5893,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
215,1816,1,1,,50105556,289,Inconclusive,,,8.9125,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
216,1828,2,1,,50105556,289,Inconclusive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
217,1850,2,1,,57264281,289,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
218,1863,2,1,,57264281,289,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
219,1865,1,1,,50105556,289,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
220,1876,1,1,,50105556,289,Inconclusive,,,11.2202,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
221,1877,1,1,,50105556,289,Inconclusive,,,12.5893,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
222,1882,1,1,,50105556,289,Inconclusive,,,11.2202,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
223,1883,1,1,,50105556,289,Active,,,10.0,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
224,1886,1,1,,50105556,289,Inconclusive,,,15.8489,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
225,1899,1,3,,57264281,289,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
226,1903,2,3,,57264281,289,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
227,1906,1,3,,57264281,289,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
228,1947,1,2,,57264281,289,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
229,1948,1,1,,17389988,289,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
230,1948,1,1,,50105556,289,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
231,1950,1,3,,57264281,289,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
232,1962,1,2,,57264281,289,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
233,1967,1,1,,85230987,289,Inconclusive,4505907.0,5376.0,75.6863,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
234,1974,1,2,,57264281,289,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
235,1987,1,2,,57264281,289,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
236,2016,1,3,,57264281,289,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
237,2023,1,3,,57264281,289,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
238,2025,1,3,,57264281,289,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
239,2029,1,3,,57264281,289,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
240,2052,2,1,,57264281,289,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
241,2057,1,2,,57264281,289,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
242,2066,1,4,,57264281,289,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
243,2101,1,1,,17389988,289,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
244,2101,1,1,,50105556,289,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
245,2101,1,1,,57264281,289,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
246,2107,1,1,,17389988,289,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
247,2107,1,1,,50105556,289,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
248,2112,1,1,,17389988,289,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
249,2112,1,1,,50105556,289,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
250,2120,1,1,,17389988,289,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
251,2129,1,2,,57264281,289,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
252,2130,1,3,,57264281,289,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
253,2147,1,1,,50105556,289,Active,221046486.0,,14.1254,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
254,2174,1,3,,57264281,289,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
255,2177,1,3,,57264281,289,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
256,2234,1,2,,57264281,289,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
257,2235,1,2,,57264281,289,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
258,2280,2,3,,57264281,289,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
259,2300,1,3,,57264281,289,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
260,2323,1,1,,50105556,289,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
261,2326,1,1,,50105556,289,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
262,2353,1,3,,50105556,289,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
263,2364,1,2,,50105556,289,Inconclusive,4557365.0,641.0,44.6684,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
264,2380,1,2,,57264281,289,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
265,2391,1,1,,57264281,289,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
266,2435,1,2,,57264281,289,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
267,2445,1,2,,57264281,289,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
268,2451,1,2,,50105556,289,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
269,2462,1,1,,57264281,289,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
270,2462,1,1,,57264281,289,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
271,2517,2,1,,17389988,289,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
272,2517,2,1,,50105556,289,Active,6980812.0,,28.1838,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
273,2517,2,1,,57264281,289,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
274,2520,1,4,,57264281,289,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
275,2521,1,3,,57264281,289,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
276,2524,1,2,,57264281,289,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
277,2528,1,2,,50105556,289,Inconclusive,4557365.0,641.0,44.6684,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
278,2540,1,2,,57264281,289,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
279,2544,1,2,,57264281,289,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
280,2546,1,1,,17389988,289,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
281,2549,1,1,,17389988,289,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
282,2549,1,1,,50105556,289,Active,282403581.0,,15.8489,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
283,2551,1,1,,17389988,289,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
284,2557,1,3,,57264281,289,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
285,2565,1,1,,50105556,289,Inactive,405898.0,,,Potency,Counterscreen for APE1 Inhibitors: qHTS Assay for Inhibitors of Endonuclease IV,Confirmatory,,
286,2572,1,1,,50105556,289,Inactive,6980812.0,,,Potency,Confirmation qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
287,2599,1,2,,57264281,289,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
288,2606,1,2,,57264281,289,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
289,2629,1,1,,57264281,289,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
290,2650,2,1,,57264281,289,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
291,2660,1,1,,90341698,289,Inconclusive,4826730.0,2475.0,23.2809,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
292,2661,1,1,,57264281,289,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
293,2662,2,1,,85230987,289,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
294,2666,1,1,,90341698,289,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
295,2667,1,1,,90341698,289,Inconclusive,4826730.0,2475.0,0.9268,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
296,2668,1,1,,90341698,289,Active,4826730.0,2475.0,10.3992,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
297,2675,1,1,,50105556,289,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
298,2676,1,2,,57264281,289,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
299,2685,1,1,,57264281,289,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
300,2690,1,2,,57264281,289,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
301,2716,1,1,,57264281,289,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
302,2717,1,2,,57264281,289,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
303,2718,1,1,,57264281,289,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
304,2732,1,1,,17404843,289,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
305,2751,2,2,,57264281,289,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
306,2774,1,3,,92303454,289,Inactive,,,,,LOPAC Circadian Assay,Screening,,
307,2796,1,4,,57264281,289,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
308,2797,1,2,,57264281,289,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
309,2805,2,2,,57264281,289,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
310,2806,2,2,,57264281,289,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
311,2825,1,2,,57264281,289,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
312,3249,9,2,,103196138,289,Unspecified,,,880.0,Ki,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Confirmatory,11412967.0,
313,3250,9,2,,103196138,289,Unspecified,,,630.0,Ki,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Confirmatory,11412967.0,
314,3251,6,4,,103196138,289,Active,,,18.0,Km,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Confirmatory,11412967.0,
315,3252,6,4,,103196138,289,Active,,,16.0,Km,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Confirmatory,11412967.0,
316,24226,3,3,,103196138,289,Unspecified,,,,,Partition coefficient (logP),Other,2993621.0,
317,28931,4,4,,103196138,289,Unspecified,,,,,Logarithm of cumulative stability constant was determined,Other,8355246.0,
318,29366,4,3,,103196138,289,Unspecified,,,,,Acid dissociation constant (pKa1) was determined,Other,8355246.0,
319,29379,4,3,,103196138,289,Unspecified,,,,,Acid dissociation constant (pKa2) was determined,Other,8355246.0,
320,226172,3,8,,103196138,289,Unspecified,,,,,Compound was evaluated for inhibition of xanthine oxidase,Other,,
321,226669,6,3,,103196138,289,Active,,,0.01,IC50,Compound was evaluated for hydroxyl radical (OH) scavenging activity,Confirmatory,,
322,226671,6,3,,103196138,289,Active,,,30.0,IC50,Superoxide anion (O2-) scavenging activity,Confirmatory,,
323,282833,4,4,,103196138,289,Unspecified,,,,,Activity against caspase-mediated apoptosis in mouse L1210 cells at 0.1 mM,Other,16279782.0,
324,282835,6,2,,103196138,289,Unspecified,,,,IC50,Cytotoxicity against mouse L1210 cells,Confirmatory,16279782.0,
325,311367,3,6,,103196138,289,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
326,314588,7,6,,103196138,289,Unspecified,21431789.0,,59.0,IC50,Antagonist activity at LuxP receptor in Vibrio harveyi MM32 assessed as inhibition of autoinducer-2-mediated quorum sensing after 3 to 4 hrs,Confirmatory,18262415.0,
327,314590,3,3,,103196138,289,Inactive,,,,,Growth inhibition of Vibrio harveyi assessed as time required to double bacterial growth relative to control,Other,18262415.0,
328,331291,9,5,,103196138,289,Unspecified,115449.0,759.0,4003.0,Ki,Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydrase assay,Confirmatory,18501600.0,
329,331292,9,5,,103196138,289,Active,115456.0,760.0,9.91,Ki,Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay,Confirmatory,18501600.0,
330,331293,9,5,,103196138,289,Active,30580362.0,80733.0,10.2,Ki,Inhibition of mouse recombinant carbonic anhydrase 15 by stopped-flow CO2 hydrase assay,Confirmatory,18501600.0,
331,334482,3,4,,103196138,289,Unspecified,,,,,Inhibition of soybean 15-LOX at 33 ug/ml,Other,8377015.0,
332,334483,3,4,,103196138,289,Unspecified,,,,,Inhibition of soybean 15-LOX at 3.6 uM,Other,8377015.0,
333,334484,3,4,,103196138,289,Unspecified,,,,,Inhibition of soybean 15-LOX at 0.36 uM,Other,8377015.0,
334,342475,9,5,,103196138,289,Unspecified,115449.0,759.0,4003.0,Ki,Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
335,342476,9,5,,103196138,289,Active,115456.0,760.0,9.9,Ki,Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
336,342477,9,5,,103196138,289,Active,134047703.0,761.0,13.0,Ki,Inhibition of human carbonic anhydrase 3 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
337,342478,9,5,,103196138,289,Active,115465.0,762.0,10.9,Ki,Inhibition of human carbonic anhydrase 4 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
338,342479,9,5,,103196138,289,Unspecified,461680.0,763.0,55.1,Ki,Inhibition of human carbonic anhydrase 5A by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
339,342480,9,5,,103196138,289,Active,8928041.0,11238.0,4.2,Ki,Inhibition of human carbonic anhydrase 5B by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
340,342481,9,5,,103196138,289,Unspecified,116241278.0,765.0,606.0,Ki,Inhibition of human carbonic anhydrase 6 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
341,342482,9,5,,103196138,289,Unspecified,1168744.0,766.0,714.0,Ki,Inhibition of human carbonic anhydrase 7 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
342,342483,9,5,,103196138,289,Unspecified,83300925.0,768.0,115.0,Ki,Inhibition of human carbonic anhydrase 9 catalytic domain by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
343,342484,9,5,,103196138,289,Active,5915866.0,771.0,8.9,Ki,Inhibition of human carbonic anhydrase 12 catalytic domain by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
344,342485,9,5,,103196138,289,Active,8928036.0,23632.0,48.9,Ki,Inhibition of human carbonic anhydrase 14 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
345,342486,9,5,,103196138,289,Active,30580372.0,71934.0,12.2,Ki,Inhibition of mouse carbonic anhydrase 13 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
346,420491,6,2,,103196138,289,Unspecified,,,80.65,IC50,Antimalarial activity against Plasmodium falciparum K1,Confirmatory,19084293.0,
347,420494,7,2,,103196138,289,Unspecified,,,,,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Other,19084293.0,
348,420495,7,2,,103196138,289,Unspecified,,,,,Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay,Other,19084293.0,
349,420496,7,2,,103196138,289,Unspecified,,,,,Cytotoxicity against human SF295 cells after 72 hrs by MTT assay,Other,19084293.0,
350,420497,7,2,,103196138,289,Unspecified,,,,,Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay,Other,19084293.0,
351,434955,1,2,,57264281,289,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
352,434962,1,2,,57264281,289,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
353,434973,1,3,,57264281,289,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
354,434989,1,1,,57264281,289,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
355,435003,1,3,,57264281,289,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
356,435005,1,1,,57264281,289,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
357,435022,2,2,,57264281,289,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
358,435030,1,2,,57264281,289,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
359,435030,1,2,,57264281,289,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
360,449728,1,2,,57264281,289,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
361,449762,1,2,,57264281,289,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
362,449763,1,3,,57264281,289,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
363,462270,8,5,,103196138,289,Unspecified,115449.0,759.0,4003.0,Ki,Inhibition of human CA1 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
364,462271,8,5,,103196138,289,Active,115456.0,760.0,9.9,Ki,Inhibition of human CA2 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
365,462272,8,5,,103196138,289,Active,134047703.0,761.0,13.0,Ki,Inhibition of human CA3 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
366,462273,8,5,,103196138,289,Active,115465.0,762.0,10.9,Ki,Inhibition of human CA4 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
367,462274,8,5,,103196138,289,Unspecified,461680.0,763.0,55.1,Ki,Inhibition of human CA5A by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
368,462275,8,5,,103196138,289,Active,8928041.0,11238.0,4.2,Ki,Inhibition of human CA5B by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
369,462276,8,5,,103196138,289,Unspecified,116241278.0,765.0,606.0,Ki,Inhibition of human CA6 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
370,462277,8,5,,103196138,289,Unspecified,1168744.0,766.0,714.0,Ki,Inhibition of human CA7 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
371,462278,8,5,,103196138,289,Unspecified,83300925.0,768.0,115.0,Ki,Inhibition of human CA9 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
372,462279,8,5,,103196138,289,Active,5915866.0,771.0,8.9,Ki,Inhibition of human CA12 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
373,462280,8,5,,103196138,289,Active,30580372.0,71934.0,12.2,Ki,Inhibition of mouse CA13 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
374,462281,8,5,,103196138,289,Active,8928036.0,23632.0,48.9,Ki,Inhibition of human CA14 by stopped-flow CO2 hydration assay,Confirmatory,20185318.0,
375,463079,1,2,,57264281,289,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
376,463082,1,1,,57264281,289,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
377,463096,1,1,,50105556,289,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
378,463097,1,1,,50105556,289,Inconclusive,7705682.0,51053.0,11.2202,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
379,463104,1,2,,57264281,289,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
380,463106,1,2,,90341698,289,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
381,463141,1,2,,57264281,289,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
382,463189,1,1,,53777386,289,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
383,463190,1,2,,57264281,289,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
384,463195,1,2,,57264281,289,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
385,463210,1,2,,57264281,289,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
386,463212,1,1,,57264281,289,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
387,463254,1,1,,57264281,289,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
388,485270,1,1,,57264281,289,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
389,485272,1,1,,57264281,289,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
390,485273,2,1,,57264281,289,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
391,485275,1,3,,57264281,289,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
392,485290,1,1,,17389988,289,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
393,485290,1,1,,50105556,289,Inconclusive,20150581.0,,19.9526,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
394,485294,1,1,,57264281,289,Inconclusive,119389684.0,,5.6234,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
395,485295,1,2,,90341698,289,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
396,485297,1,1,,57264281,289,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
397,485297,1,1,,90341698,289,Inactive,4759012.0,9367.0,73.078,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
398,485298,1,1,,57264281,289,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
399,485298,1,1,,90341698,289,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
400,485313,1,2,,57264281,289,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
401,485313,1,2,,90341698,289,Inactive,255652944.0,4864.0,115.821,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
402,485314,1,1,,50105556,289,Active,4505931.0,5423.0,39.8107,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
403,485317,1,2,,57264281,289,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
404,485341,1,1,,57264281,289,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
405,485342,1,2,,90341698,289,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
406,485345,1,2,,90341698,289,Inconclusive,,,29.0929,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
407,485346,1,1,,57264281,289,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
408,485346,1,1,,57264281,289,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
409,485347,1,2,,57264281,289,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
410,485349,1,1,,57264281,289,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
411,485360,1,1,,57264281,289,Active,117938328.0,26013.0,17.7828,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
412,485364,1,1,,57264281,289,Active,15149312.0,8345881.0,15.8489,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
413,485366,1,2,,90341698,289,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
414,485367,1,2,,57264281,289,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
415,485368,1,2,,90341698,289,Inconclusive,72386991.0,3656265.0,5.3582,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
416,488745,1,4,,85230987,289,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
417,488752,1,4,,85230987,289,Inconclusive,,,13.1154,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
418,488772,1,1,,90341698,289,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
419,488773,1,2,,90341698,289,Active,8659577.0,58819.0,11.9173,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
420,488816,1,1,,90341698,289,Active,4758356.0,2237.0,5.9728,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
421,488837,1,1,,57264281,289,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
422,488837,1,1,,90341698,289,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
423,488839,1,1,,57264281,289,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
424,488839,1,1,,57264281,289,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
425,488847,1,3,,57264281,289,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
426,488862,1,1,,57264281,289,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
427,488890,1,2,,57264281,289,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
428,488895,1,2,,57264281,289,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
429,488896,1,1,,57264281,289,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
430,488899,1,1,,57264281,289,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
431,488949,1,2,,85230987,289,Active,41055989.0,54737.0,79.4328,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
432,488949,1,2,,90341698,289,Inconclusive,41055989.0,54737.0,26.6795,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
433,488953,1,1,,90341698,289,Inconclusive,187960037.0,10951.0,50.1187,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
434,488965,1,2,,57264281,289,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
435,488966,1,1,,57264281,289,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
436,488975,1,2,,57264281,289,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
437,488977,1,2,,57264281,289,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
438,488978,1,1,,90341698,289,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
439,488979,1,1,,50105556,289,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
440,488980,1,1,,85230987,289,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
441,488981,1,1,,90341698,289,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
442,488982,1,1,,90341698,289,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
443,488983,1,1,,90341698,289,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
444,489030,2,1,,57264281,289,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
445,489031,2,1,,57264281,289,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
446,492947,1,1,,57264281,289,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
447,492953,1,1,,57264281,289,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
448,492956,1,1,,57264281,289,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
449,492972,1,1,,57264281,289,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
450,493005,1,1,,57264281,289,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
451,493008,1,1,,57264281,289,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
452,493008,1,1,,57264281,289,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
453,493008,1,1,,57264281,289,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
454,493008,1,1,,57264281,289,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
455,493011,1,1,,57264281,289,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
456,493012,1,1,,57264281,289,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
457,493014,1,1,,57264281,289,Inconclusive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
458,493036,1,2,,57264281,289,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
459,493056,1,1,,57264281,289,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
460,493084,1,1,,57264281,289,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
461,493087,1,1,,57264281,289,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
462,493091,1,1,,57264281,289,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
463,493098,1,1,,57264281,289,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
464,493106,1,1,,90341698,289,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
465,493107,1,1,,90341698,289,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
466,493127,1,1,,50105556,289,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
467,493131,1,1,,57264281,289,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
468,493153,1,1,,90341698,289,Inconclusive,,4780.0,23.1093,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
469,493153,1,1,,90341698,289,Inconclusive,224028257.0,4780.0,23.1093,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
470,493160,1,1,,57264281,289,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
471,493164,1,2,,90341698,289,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
472,493164,1,2,,90341698,289,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
473,493164,1,2,,90341698,289,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
474,493187,1,2,,57264281,289,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
475,493189,1,1,,50105556,289,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
476,493244,1,1,,57264281,289,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
477,493244,1,1,,57264281,289,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
478,493244,1,1,,57264281,289,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
479,493244,1,1,,57264281,289,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
480,504326,1,2,,57264281,289,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
481,504326,1,2,,57264281,289,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
482,504327,1,1,,57264281,289,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
483,504327,1,1,,90341698,289,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
484,504329,1,1,,57264281,289,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
485,504332,1,1,,50105556,289,Active,168985070.0,,1.5849,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
486,504332,1,1,,57264281,289,Active,168985070.0,,1.2589,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
487,504332,1,1,,90341698,289,Active,168985070.0,,1.7783,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
488,504333,1,1,,57264281,289,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
489,504339,1,1,,57264281,289,Active,162330054.0,,39.8107,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
490,504357,1,1,,57264281,289,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
491,504357,1,1,,57264281,289,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
492,504364,1,1,,85230987,289,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
493,504406,1,1,,57264281,289,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
494,504411,1,1,,57264281,289,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
495,504414,1,1,,57264281,289,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
496,504414,1,1,,57264281,289,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
497,504423,1,1,,57264281,289,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
498,504441,1,1,,57264281,289,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
499,504444,1,1,,57264281,289,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
500,504454,1,3,,57264281,289,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
501,504462,1,1,,57264281,289,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
502,504466,1,1,,57264281,289,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
503,504467,1,1,,57264281,289,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
504,504490,1,2,,57264281,289,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
505,504523,1,1,,57264281,289,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
506,504523,1,1,,57264281,289,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
507,504536,1,1,,90341698,289,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
508,504547,1,1,,90341698,289,Inconclusive,115503961.0,4357161.0,30.1313,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
509,504548,1,2,,90341698,289,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
510,504558,1,1,,57264281,289,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
511,504577,2,2,,57264281,289,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
512,504582,2,1,,57264281,289,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
513,504621,1,1,,57264281,289,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
514,504634,1,1,,57264281,289,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
515,504648,1,1,,57264281,289,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
516,504651,1,1,,57264281,289,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
517,504652,1,1,,57264281,289,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
518,504660,1,1,,57264281,289,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
519,504690,1,3,,57264281,289,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
520,504692,2,2,,57264281,289,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
521,504700,1,1,,57264281,289,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
522,504700,1,1,,57264281,289,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
523,504706,1,1,,57264281,289,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
524,504707,1,1,,57264281,289,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
525,504707,1,1,,57264281,289,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
526,504720,1,1,,57264281,289,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
527,504734,1,1,,57264281,289,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
528,504766,2,1,,57264281,289,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
529,504775,1,1,,57264281,289,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
530,504803,1,1,,57264281,289,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
531,504810,1,2,,57264281,289,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
532,504810,1,2,,90341698,289,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
533,504812,1,2,,57264281,289,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
534,504812,1,2,,90341698,289,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
535,504821,1,1,,85230987,289,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
536,504832,1,1,,57264281,289,Inconclusive,,,11.6891,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
537,504834,1,1,,57264281,289,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
538,504836,1,2,,90341698,289,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
539,504842,1,1,,57264281,289,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
540,504845,1,1,,57264281,289,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
541,504845,1,1,,90341698,289,Inconclusive,86301163.0,5999.0,18.8876,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
542,504847,1,1,,57264281,289,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
543,504847,1,1,,90341698,289,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
544,504865,1,1,,90341698,289,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
545,504884,1,2,,57264281,289,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
546,504891,1,1,,57264281,289,Inconclusive,5453898.0,5300.0,79.4328,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
547,504894,1,1,,57264281,289,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
548,504937,1,2,,57264281,289,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
549,521220,3,3,,103196138,289,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
550,524790,7,2,,103196138,289,Active,,,10.0,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
551,524791,7,2,,103196138,289,Active,,,10.0,IC50,Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
552,524792,7,2,,103196138,289,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
553,524794,7,1,,103196138,289,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
554,524795,7,2,,103196138,289,Active,,,15.8489,IC50,Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
555,524796,7,1,,103196138,289,Active,,,10.0,IC50,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
556,540253,1,1,,57264281,289,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
557,540253,1,1,,57264281,289,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
558,540253,1,1,,57264281,289,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
559,540256,1,2,,50105556,289,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
560,540256,1,2,,90341698,289,Inconclusive,,,11.5774,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
561,540263,1,1,,57264281,289,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
562,540263,1,1,,57264281,289,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
563,540267,1,1,,57264281,289,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
564,540275,1,1,,57264281,289,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
565,540276,1,2,,11111004,289,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
566,540276,1,2,,17389988,289,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
567,540276,1,2,,50105556,289,Active,420597.0,,2.5119,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
568,540276,1,2,,50105557,289,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
569,540276,1,2,,57264281,289,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
570,540276,1,2,,85230987,289,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
571,540276,1,2,,90341698,289,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
572,540277,1,1,,57264281,289,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
573,540295,1,1,,57264281,289,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
574,540303,1,1,,57264281,289,Inconclusive,6679377.0,18792.0,1.7783,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
575,540303,1,1,,57264281,289,Inconclusive,7242179.0,18793.0,1.7783,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
576,540303,1,1,,57264281,289,Inconclusive,257471003.0,18815.0,1.7783,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
577,540308,1,1,,57264281,289,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
578,540317,1,1,,57264281,289,Inconclusive,187960037.0,10951.0,70.7946,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
579,540336,1,1,,57264281,289,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
580,540336,1,1,,57264281,289,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
581,540364,1,2,,57264281,289,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
582,566699,3,7,,103196138,289,Unspecified,6686057.0,,,,Inhibition of mushroom tyrosinase at 1 mM after 10 mins,Other,21189019.0,
583,566700,3,7,,103196138,289,Unspecified,126407.0,240.0,,,Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay,Other,21189019.0,
584,566701,3,8,,103196138,289,Unspecified,50402185.0,,,,Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay,Other,21189019.0,
585,566702,2,9,,103196138,289,Unspecified,116852.0,4312.0,,,Inhibition of human recombinant MMP1 at 1 mM after 30 mins,Other,21189019.0,
586,566703,3,7,,103196138,289,Unspecified,116856.0,4313.0,,,Inhibition of human recombinant MMP2 at 1 mM after 30 mins,Other,21189019.0,
587,566704,2,9,,103196138,289,Unspecified,116857.0,4314.0,,,Inhibition of human recombinant MMP3 at 1 mM after 30 mins,Other,21189019.0,
588,566705,3,7,,103196138,289,Unspecified,116862.0,4317.0,,,Inhibition of human recombinant MMP8 at 1 mM after 30 mins,Other,21189019.0,
589,566706,3,7,,103196138,289,Unspecified,269849668.0,4318.0,,,Inhibition of human recombinant MMP9 at 1 mM after 30 mins,Other,21189019.0,
590,566707,3,7,,103196138,289,Unspecified,266649.0,18126.0,,,Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay,Other,21189019.0,
591,588334,1,1,,57264281,289,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
592,588335,1,1,,57264281,289,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
593,588342,1,1,,57264281,289,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
594,588349,1,1,,90341698,289,Inconclusive,,,35.4813,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
595,588352,1,2,,57264281,289,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
596,588354,1,1,,57264281,289,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
597,588358,1,2,,57264281,289,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
598,588378,1,1,,90341698,289,Inconclusive,171543895.0,6311.0,39.8107,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
599,588391,1,1,,57264281,289,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
600,588405,1,1,,57264281,289,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
601,588413,1,2,,57264281,289,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
602,588436,1,1,,57264281,289,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
603,588453,1,1,,57264281,289,Inconclusive,8659577.0,58819.0,17.7828,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
604,588453,1,1,,85230987,289,Inconclusive,8659577.0,58819.0,26.6795,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
605,588453,1,1,,90341698,289,Inconclusive,8659577.0,58819.0,11.9173,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
606,588456,1,1,,57264281,289,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
607,588456,1,1,,90341698,289,Inactive,8659577.0,58819.0,0.631,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
608,588458,1,1,,57264281,289,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
609,588473,1,1,,57264281,289,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
610,588473,1,1,,57264281,289,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
611,588475,1,2,,57264281,289,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
612,588475,1,2,,57264281,289,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
613,588478,1,2,,124800355,289,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
614,588489,1,1,,57264281,289,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
615,588492,1,1,,57264281,289,Active,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
616,588493,1,2,,57264281,289,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
617,588497,1,2,,57264281,289,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
618,588497,1,2,,57264281,289,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
619,588497,1,2,,57264281,289,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
620,588499,1,3,,57264281,289,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
621,588499,1,3,,57264281,289,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
622,588499,1,3,,57264281,289,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
623,588501,1,2,,57264281,289,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
624,588501,1,2,,57264281,289,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
625,588501,1,2,,57264281,289,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
626,588511,1,2,,57264281,289,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
627,588513,1,1,,17389988,289,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
628,588514,1,1,,17389988,289,Active,348019627.0,2099.0,5.0119,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
629,588515,1,1,,17389988,289,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
630,588516,1,1,,17389988,289,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
631,588526,1,1,,17389988,289,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
632,588527,1,1,,17389988,289,Inconclusive,325495553.0,9971.0,22.3872,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
633,588532,1,1,,17389988,289,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
634,588533,1,1,,17389988,289,Active,311348376.0,2908.0,35.4813,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
635,588534,1,1,,17389988,289,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
636,588535,1,1,,17389988,289,Inconclusive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
637,588536,1,1,,17389988,289,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
638,588537,1,1,,17389988,289,Inconclusive,216409692.0,5468.0,44.6684,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
639,588541,1,1,,17389988,289,Inconclusive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
640,588543,1,1,,17389988,289,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
641,588544,1,1,,17389988,289,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
642,588545,1,1,,17389988,289,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
643,588546,1,1,,17389988,289,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
644,588547,1,1,,17389988,289,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
645,588549,1,1,,57264281,289,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
646,588579,1,1,,57264281,289,Active,7705344.0,51426.0,50.1187,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
647,588579,1,1,,90341698,289,Inconclusive,7705344.0,51426.0,37.6858,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
648,588590,1,1,,50105556,289,Inconclusive,154350220.0,11201.0,25.1189,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
649,588590,1,1,,57264281,289,Active,154350220.0,11201.0,79.4328,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
650,588591,1,1,,50105556,289,Inconclusive,5729982.0,5429.0,31.6228,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
651,588591,1,1,,57264281,289,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
652,588621,1,1,,57264281,289,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
653,588627,1,1,,57264281,289,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
654,588664,1,2,,57264281,289,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
655,588664,1,2,,57264281,289,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
656,588674,1,2,,57264281,289,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
657,588675,1,1,,57264281,289,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
658,588676,1,1,,57264281,289,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
659,588689,1,1,,57264281,289,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
660,588692,2,1,,57264281,289,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
661,588726,1,2,,57264281,289,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
662,588727,1,1,,57264281,289,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
663,588795,1,1,,57264281,289,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
664,588795,1,1,,90341698,289,Active,4758356.0,2237.0,5.9728,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
665,588812,1,1,,17389988,289,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
666,588812,1,1,1.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
667,588812,1,1,2.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
668,588812,1,1,3.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
669,588812,1,1,4.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
670,588812,1,1,5.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
671,588812,1,1,6.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
672,588812,1,1,7.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
673,588812,1,1,8.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
674,588812,1,1,9.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
675,588812,1,1,10.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
676,588812,1,1,11.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
677,588812,1,1,12.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
678,588812,1,1,13.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
679,588812,1,1,14.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
680,588812,1,1,15.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
681,588812,1,1,16.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
682,588812,1,1,17.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
683,588812,1,1,18.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
684,588812,1,1,19.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
685,588812,1,1,20.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
686,588812,1,1,21.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
687,588812,1,1,22.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
688,588812,1,1,23.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
689,588812,1,1,24.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
690,588812,1,1,25.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
691,588812,1,1,26.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
692,588812,1,1,27.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
693,588812,1,1,28.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
694,588812,1,1,29.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
695,588812,1,1,30.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
696,588812,1,1,31.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
697,588812,1,1,32.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
698,588812,1,1,33.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
699,588812,1,1,34.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
700,588812,1,1,35.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
701,588812,1,1,36.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
702,588812,1,1,37.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
703,588812,1,1,38.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
704,588812,1,1,39.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
705,588812,1,1,40.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
706,588812,1,1,41.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
707,588812,1,1,42.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
708,588812,1,1,43.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
709,588812,1,1,44.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
710,588812,1,1,45.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
711,588812,1,1,46.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
712,588812,1,1,47.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
713,588812,1,1,48.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
714,588812,1,1,49.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
715,588812,1,1,50.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
716,588812,1,1,51.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
717,588812,1,1,52.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
718,588812,1,1,53.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
719,588812,1,1,54.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
720,588812,1,1,55.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
721,588812,1,1,56.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
722,588812,1,1,57.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
723,588812,1,1,58.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
724,588812,1,1,59.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
725,588812,1,1,60.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
726,588812,1,1,61.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
727,588812,1,1,62.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
728,588812,1,1,63.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
729,588812,1,1,64.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
730,588812,1,1,65.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
731,588812,1,1,66.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
732,588812,1,1,67.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
733,588812,1,1,68.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
734,588812,1,1,69.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
735,588812,1,1,70.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
736,588812,1,1,71.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
737,588812,1,1,72.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
738,588812,1,1,73.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
739,588812,1,1,74.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
740,588812,1,1,75.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
741,588812,1,1,76.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
742,588812,1,1,77.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
743,588812,1,1,78.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
744,588812,1,1,79.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
745,588812,1,1,80.0,17389988,289,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
746,588812,1,1,81.0,17389988,289,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
747,588813,1,1,,17389988,289,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
748,588813,1,1,1.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
749,588813,1,1,2.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
750,588813,1,1,3.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
751,588813,1,1,4.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
752,588813,1,1,5.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
753,588813,1,1,6.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
754,588813,1,1,7.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
755,588813,1,1,8.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
756,588813,1,1,9.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
757,588813,1,1,10.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
758,588813,1,1,11.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
759,588813,1,1,12.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
760,588813,1,1,13.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
761,588813,1,1,14.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
762,588813,1,1,15.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
763,588813,1,1,16.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
764,588813,1,1,17.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
765,588813,1,1,18.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
766,588813,1,1,19.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
767,588813,1,1,20.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
768,588813,1,1,21.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
769,588813,1,1,22.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
770,588813,1,1,23.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
771,588813,1,1,24.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
772,588813,1,1,25.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
773,588813,1,1,26.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
774,588813,1,1,27.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
775,588813,1,1,28.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
776,588813,1,1,29.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
777,588813,1,1,30.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
778,588813,1,1,31.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
779,588813,1,1,32.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
780,588813,1,1,33.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
781,588813,1,1,34.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
782,588813,1,1,35.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
783,588813,1,1,36.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
784,588813,1,1,37.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
785,588813,1,1,38.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
786,588813,1,1,39.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
787,588813,1,1,40.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
788,588813,1,1,41.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
789,588813,1,1,42.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
790,588813,1,1,43.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
791,588813,1,1,44.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
792,588813,1,1,45.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
793,588813,1,1,46.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
794,588813,1,1,47.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
795,588813,1,1,48.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
796,588813,1,1,49.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
797,588813,1,1,50.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
798,588813,1,1,51.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
799,588813,1,1,52.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
800,588813,1,1,53.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
801,588813,1,1,54.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
802,588813,1,1,55.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
803,588813,1,1,56.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
804,588813,1,1,57.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
805,588813,1,1,58.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
806,588813,1,1,59.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
807,588813,1,1,60.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
808,588813,1,1,61.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
809,588813,1,1,62.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
810,588813,1,1,63.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
811,588813,1,1,64.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
812,588813,1,1,65.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
813,588813,1,1,66.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
814,588813,1,1,67.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
815,588813,1,1,68.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
816,588813,1,1,69.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
817,588813,1,1,70.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
818,588813,1,1,71.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
819,588813,1,1,72.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
820,588813,1,1,73.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
821,588813,1,1,74.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
822,588813,1,1,75.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
823,588813,1,1,76.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
824,588813,1,1,77.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
825,588813,1,1,78.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
826,588813,1,1,79.0,17389988,289,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
827,588813,1,1,80.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
828,588813,1,1,81.0,17389988,289,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
829,588814,1,3,,57264281,289,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
830,588819,1,4,,57264281,289,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
831,588834,2,1,,17389988,289,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
832,588834,2,1,,50105556,289,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
833,588850,1,1,,57264281,289,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
834,588852,1,3,,57264281,289,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
835,588855,1,1,,57264281,289,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
836,588856,1,1,,57264281,289,Inactive,,,11.2202,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
837,602123,1,1,,57264281,289,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
838,602141,1,1,,57264281,289,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
839,602162,1,1,,57264281,289,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
840,602163,1,1,,57264281,289,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
841,602179,1,2,,57264281,289,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
842,602229,1,1,,57264281,289,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
843,602233,1,1,,57264281,289,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
844,602244,1,2,,57264281,289,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
845,602247,1,2,,57264281,289,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
846,602248,1,2,,57264281,289,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
847,602250,1,2,,57264281,289,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
848,602252,1,1,,57264281,289,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
849,602252,1,1,,57264281,289,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
850,602261,1,1,,57264281,289,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
851,602274,1,2,,57264281,289,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
852,602281,1,1,,57264281,289,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
853,602281,1,1,,57264281,289,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
854,602310,1,2,,57264281,289,Inconclusive,13399304.0,60489.0,31.6228,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
855,602313,1,1,,57264281,289,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
856,602329,1,1,,57264281,289,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
857,602332,1,1,,57264281,289,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
858,602332,1,1,,90341698,289,Inconclusive,168984549.0,,13.0918,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
859,602340,1,2,,57264281,289,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
860,602342,2,1,,57264281,289,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
861,602346,1,1,,57264281,289,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
862,602363,1,1,,57264281,289,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
863,602393,1,1,,57264281,289,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
864,602396,1,2,,57264281,289,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
865,602399,1,2,,57264281,289,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
866,602405,1,1,,57264281,289,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
867,602410,1,1,,57264281,289,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
868,602429,1,1,,57264281,289,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
869,602438,1,1,,57264281,289,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
870,602440,1,1,,57264281,289,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
871,602449,1,2,,57264281,289,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
872,602481,1,1,,57264281,289,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
873,607497,6,5,,103196138,289,Active,123910379.0,,14.8,Ki,Inhibition of Dicentrarchus labrax CA using 4-nitrophenylacetate substrate by esterase assay,Confirmatory,21669522.0,
874,615280,3,2,,103196138,289,Unspecified,,,59.0,IC50,Inhibition of quorum sensing regulated bioluminescence in Vibrio harveyi,Confirmatory,20669927.0,
875,623870,1,1,,57264281,289,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
876,623870,1,1,,57264281,289,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
877,623877,1,1,,57264281,289,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
878,623901,1,1,,57264281,289,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
879,624037,1,3,,57264281,289,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
880,624038,1,3,,57264281,289,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
881,624040,1,3,,57264281,289,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
882,624125,1,4,,57264281,289,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
883,624126,1,3,,57264281,289,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
884,624127,1,2,,57264281,289,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
885,624146,1,1,,90341698,289,Active,71051501.0,2744.0,1.9953,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
886,624147,1,1,,90341698,289,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
887,624148,1,2,,90341698,289,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
888,624149,1,1,,90341698,289,Inconclusive,693842.0,4780.0,23.1093,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
889,624168,1,1,,57264281,289,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
890,624169,1,1,,57264281,289,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
891,624170,1,1,,57264281,289,Inconclusive,71051501.0,2744.0,35.4813,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
892,624171,1,1,,57264281,289,Inconclusive,693842.0,4780.0,35.4813,Potency,qHTS of Nrf2 Activators,Confirmatory,,
893,624172,1,1,,57264281,289,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
894,624173,1,3,,57264281,289,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
895,624178,1,1,,57264281,289,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
896,624202,1,1,,57264281,289,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
897,624204,1,2,,57264281,289,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
898,624246,1,1,,57264281,289,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
899,624256,1,2,,57264281,289,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
900,624263,1,1,,57264281,289,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
901,624263,1,1,,57264281,289,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
902,624267,1,2,,57264281,289,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
903,624267,1,2,,57264281,289,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
904,624268,1,3,,57264281,289,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
905,624288,1,1,,57264281,289,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
906,624296,1,1,,57264281,289,Inactive,7705682.0,51053.0,0.7308,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
907,624297,1,1,,57264281,289,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
908,624304,1,2,,57264281,289,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
909,624330,1,2,,57264281,289,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
910,624352,1,1,,57264281,289,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
911,624354,1,1,,57264281,289,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
912,624377,1,1,,57264281,289,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
913,624414,1,1,,57264281,289,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
914,624415,1,2,,57264281,289,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
915,624416,1,1,,57264281,289,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
916,624417,1,1,,57264281,289,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
917,624418,1,1,,57264281,289,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
918,624455,1,1,,90341698,289,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
919,624463,1,1,,57264281,289,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
920,624464,1,1,,57264281,289,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
921,624465,1,1,,57264281,289,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
922,624466,1,3,,57264281,289,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
923,624467,1,1,,57264281,289,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
924,624483,1,1,,57264281,289,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
925,625144,5,5,,103196138,289,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
926,625145,4,7,,103196138,289,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
927,625146,5,5,,103196138,289,Active,126397.0,100009114.0,0.868,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
928,625147,4,7,,103196138,289,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
929,625148,4,7,,103196138,289,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
930,625149,4,7,,103196138,289,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
931,625150,5,5,,103196138,289,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
932,625151,4,7,,103196138,289,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
933,625152,4,7,,103196138,289,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
934,625153,4,7,,103196138,289,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
935,625154,4,7,,103196138,289,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
936,625155,4,7,,103196138,289,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
937,625156,1,9,,103196138,289,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
938,625157,6,2,,103196138,289,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
939,625158,3,4,,103196138,289,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
940,625159,5,5,,103196138,289,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
941,625160,1,9,,103196138,289,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
942,625161,4,7,,103196138,289,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
943,625162,4,7,,103196138,289,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
944,625163,4,7,,103196138,289,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
945,625164,1,6,,103196138,289,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
946,625165,3,4,,103196138,289,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
947,625166,3,4,,103196138,289,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
948,625167,5,5,,103196138,289,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
949,625168,4,7,,103196138,289,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
950,625169,1,6,,103196138,289,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
951,625170,3,4,,103196138,289,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
952,625171,4,7,,103196138,289,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
953,625172,4,7,,103196138,289,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
954,625173,5,5,,103196138,289,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
955,625174,5,5,,103196138,289,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
956,625175,5,5,,103196138,289,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
957,625176,1,9,,103196138,289,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
958,625177,5,5,,103196138,289,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
959,625178,5,5,,103196138,289,Active,269849668.0,4318.0,23.366999999999997,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
960,625179,1,9,,103196138,289,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
961,625180,5,5,,103196138,289,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
962,625181,5,5,,103196138,289,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
963,625182,5,5,,103196138,289,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
964,625183,5,5,,103196138,289,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
965,625184,5,5,,103196138,289,Active,2811086.0,1956.0,26.043000000000003,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
966,625185,5,5,,103196138,289,Active,125370.0,2534.0,17.430999999999997,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
967,625186,5,5,,103196138,289,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
968,625187,5,5,,103196138,289,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
969,625188,1,9,,103196138,289,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
970,625189,1,7,,103196138,289,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
971,625190,4,5,,103196138,289,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
972,625191,4,7,,103196138,289,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
973,625192,4,7,,103196138,289,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
974,625193,5,5,,103196138,289,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
975,625194,4,7,,103196138,289,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
976,625195,4,7,,103196138,289,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
977,625196,5,6,,103196138,289,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
978,625197,3,4,,103196138,289,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
979,625198,4,7,,103196138,289,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
980,625199,4,7,,103196138,289,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
981,625200,4,7,,103196138,289,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
982,625201,4,7,,103196138,289,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
983,625202,4,7,,103196138,289,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
984,625203,4,7,,103196138,289,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
985,625204,4,7,,103196138,289,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
986,625205,4,7,,103196138,289,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
987,625206,4,7,,103196138,289,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
988,625207,4,7,,103196138,289,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
989,625208,5,5,,103196138,289,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
990,625209,4,7,,103196138,289,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
991,625210,3,4,,103196138,289,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
992,625211,1,6,,103196138,289,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
993,625212,3,4,,103196138,289,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
994,625213,4,7,,103196138,289,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
995,625214,1,9,,103196138,289,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
996,625215,3,4,,103196138,289,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
997,625216,3,4,,103196138,289,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
998,625217,4,7,,103196138,289,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
999,625218,4,7,,103196138,289,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1000,625219,3,4,,103196138,289,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1001,625220,4,7,,103196138,289,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1002,625221,4,7,,103196138,289,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1003,625222,4,7,,103196138,289,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1004,625223,4,7,,103196138,289,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1005,625224,3,4,,103196138,289,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1006,625225,3,4,,103196138,289,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1007,625226,4,7,,103196138,289,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1008,625227,4,7,,103196138,289,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1009,625228,4,7,,103196138,289,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1010,625229,5,5,,103196138,289,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1011,625230,1,6,,103196138,289,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1012,625231,4,7,,103196138,289,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1013,625232,1,9,,103196138,289,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1014,625233,4,7,,103196138,289,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1015,625234,3,4,,103196138,289,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1016,625235,4,7,,103196138,289,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1017,625236,5,5,,103196138,289,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1018,625237,4,7,,103196138,289,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1019,625238,4,7,,103196138,289,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1020,625239,4,7,,103196138,289,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1021,625240,1,9,,103196138,289,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1022,625241,4,7,,103196138,289,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1023,625242,4,7,,103196138,289,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1024,625243,5,5,,103196138,289,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1025,625244,5,5,,103196138,289,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1026,625245,5,5,,103196138,289,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1027,625246,1,9,,103196138,289,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1028,625247,5,5,,103196138,289,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1029,625248,5,5,,103196138,289,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1030,625249,5,5,,103196138,289,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1031,625250,5,5,,103196138,289,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1032,625251,5,5,,103196138,289,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1033,625252,4,7,,103196138,289,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1034,625253,4,7,,103196138,289,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1035,625254,4,7,,103196138,289,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1036,625255,4,7,,103196138,289,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1037,625256,4,7,,103196138,289,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1038,625257,4,7,,103196138,289,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1039,625258,4,7,,103196138,289,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1040,625259,4,7,,103196138,289,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1041,625260,3,4,,103196138,289,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1042,625261,3,4,,103196138,289,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1043,625262,3,4,,103196138,289,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1044,625263,4,7,,103196138,289,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1045,625264,3,4,,103196138,289,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1046,625265,1,6,,103196138,289,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1047,625266,3,4,,103196138,289,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1048,625267,3,4,,103196138,289,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1049,625268,4,2,,103196138,289,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1050,625268,4,2,,103196138,289,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1051,625268,4,2,,103196138,289,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1052,625268,4,2,,103196138,289,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1053,625269,4,7,,103196138,289,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1054,625270,4,7,,103196138,289,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1055,625271,5,5,,103196138,289,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1056,625272,3,4,,103196138,289,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1057,625273,4,6,,103196138,289,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1058,625274,1,6,,103196138,289,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1059,625275,3,4,,103196138,289,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1060,644084,5,5,,103196138,289,Unspecified,115449.0,759.0,4003.0,Ki,Inhibition of human carbonic anhydrase 1 using 4-nitrophenylacetate as substrate after 3 mins using spectrophotometry by Lineweaver-Burk plot analysis,Confirmatory,22245047.0,
1061,644085,5,5,,103196138,289,Active,115456.0,760.0,9.9,Ki,Inhibition of human carbonic anhydrase 2 using 4-nitrophenylacetate as substrate after 3 mins using spectrophotometry by Lineweaver-Burk plot analysis,Confirmatory,22245047.0,
1062,644086,5,5,,103196138,289,Active,115465.0,762.0,10.9,Ki,Inhibition of human carbonic anhydrase 4 using 4-nitrophenylacetate as substrate after 3 mins using spectrophotometry by Lineweaver-Burk plot analysis,Confirmatory,22245047.0,
1063,644087,5,5,,103196138,289,Unspecified,116241278.0,765.0,606.0,Ki,Inhibition of human carbonic anhydrase 6 using 4-nitrophenylacetate as substrate after 3 mins using spectrophotometry by Lineweaver-Burk plot analysis,Confirmatory,22245047.0,
1064,644088,5,5,,103196138,289,Active,118572923.0,513212.0,3.48,Ki,Inhibition of bovine carbonic anhydrase 3 using 4-nitrophenylacetate as substrate after 3 mins using spectrophotometry by Lineweaver-Burk plot analysis,Confirmatory,22245047.0,
1065,651550,1,1,,57264281,289,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1066,651560,1,1,,57264281,289,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1067,651572,1,2,,57264281,289,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1068,651582,1,1,,57264281,289,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1069,651602,1,1,,57264281,289,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1070,651602,1,1,,57264281,289,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1071,651602,1,1,,57264281,289,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1072,651610,2,1,,57264281,289,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1073,651631,4,1,,144209515,289,Inconclusive,269849759.0,7157.0,49.1509,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1074,651631,4,1,,144210473,289,Inconclusive,269849759.0,7157.0,1.2197,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1075,651632,4,1,,144209515,289,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1076,651632,4,1,,144210473,289,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1077,651633,4,1,,144209515,289,Active,,,43.8058,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1078,651633,4,1,,144210473,289,Active,,,30.6379,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1079,651634,4,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1080,651634,4,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1081,651635,1,3,,57264281,289,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1082,651635,1,3,,90341698,289,Inconclusive,171543895.0,6311.0,35.4813,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1083,651636,1,1,,57264281,289,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1084,651640,1,1,,57264281,289,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1085,651644,1,1,,57264281,289,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1086,651647,1,1,,57264281,289,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1087,651654,1,1,,57264281,289,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1088,651658,1,1,,57264281,289,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1089,651661,2,1,,57264281,289,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1090,651687,1,1,,57264281,289,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1091,651699,1,1,,57264281,289,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1092,651699,1,1,,57264281,289,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1093,651702,1,2,,57264281,289,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1094,651704,2,1,,57264281,289,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1095,651710,1,1,,57264281,289,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1096,651711,2,1,,57264281,289,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1097,651718,1,2,,57264281,289,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1098,651719,1,2,,57264281,289,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
1099,651723,1,1,,57264281,289,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1100,651724,1,1,,57264281,289,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1101,651725,1,1,,57264281,289,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1102,651741,1,1,,17389988,289,Active,20149576.0,4780.0,29.8493,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1103,651743,1,1,,17389988,289,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1104,651749,1,1,,17389988,289,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1105,651751,1,1,,17389988,289,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1106,651754,1,1,,17389988,289,Inconclusive,,,37.578,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
1107,651755,1,1,,17389988,289,Inconclusive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
1108,651757,1,1,,17389988,289,Inconclusive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
1109,651758,1,1,,17389988,289,Inconclusive,186368.0,3576.0,74.97800000000001,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
1110,651768,1,2,,57264281,289,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1111,651777,1,1,,17389988,289,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1112,651778,1,1,,17389988,289,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1113,651800,1,1,,57264281,289,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1114,651802,1,1,,17389988,289,Active,49066040.0,6097.0,5.9557,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1115,651819,1,1,,57264281,289,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1116,651820,1,1,,57264281,289,Inconclusive,,,3.1623,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1117,651821,2,4,,57264281,289,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1118,651828,1,2,,121360966,289,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1119,651838,1,1,,17389988,289,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1120,651838,1,1,1.0,17389988,289,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1121,651838,1,1,2.0,17389988,289,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1122,651838,1,1,3.0,17389988,289,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1123,651838,1,1,4.0,17389988,289,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1124,651838,1,1,5.0,17389988,289,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1125,651838,1,1,6.0,17389988,289,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1126,651838,1,1,7.0,17389988,289,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1127,651838,1,1,8.0,17389988,289,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1128,651957,1,1,,57264281,289,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1129,651958,1,1,,57264281,289,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1130,651965,1,1,,57264281,289,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1131,651999,1,1,,57264281,289,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1132,652010,1,1,,57264281,289,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1133,652017,1,1,,57264281,289,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1134,652025,1,1,,57264281,289,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1135,652039,1,1,,57264281,289,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1136,652048,1,2,,57264281,289,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1137,652051,1,1,,57264281,289,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1138,652054,1,1,,57264281,289,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1139,652067,1,4,,57264281,289,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1140,652104,1,1,,57264281,289,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1141,652105,1,1,,57264281,289,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1142,652106,1,1,,57264281,289,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1143,652106,1,1,,90341698,289,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1144,652115,1,1,,57264281,289,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1145,652126,1,3,,57264281,289,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1146,652154,1,1,,57264281,289,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1147,652162,2,1,,57264281,289,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1148,652163,1,1,,57264281,289,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1149,652197,1,1,,57264281,289,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1150,652257,1,1,,57264281,289,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1151,686940,1,1,,57264281,289,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1152,686964,1,1,,57264281,289,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1153,686970,1,2,,57264281,289,Inconclusive,49168486.0,3417.0,10.3225,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1154,686971,1,2,,57264281,289,Inconclusive,,,18.3564,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1155,686978,1,1,,57264281,289,Inconclusive,79154014.0,55775.0,29.0929,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1156,686979,1,1,,57264281,289,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1157,686992,2,1,,57264281,289,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
1158,686996,1,1,,57264281,289,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1159,687014,1,1,,57264281,289,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1160,687016,1,1,,57264281,289,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1161,687035,1,1,,163564234,289,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
1162,687037,1,3,,163564234,289,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
1163,691690,2,3,,103196138,289,Active,,,36.0,IC50,Antioxidant activity of the compound assessed as DPPH radical scavenging activity,Confirmatory,22995623.0,
1164,714146,1,2,,103196138,289,Unspecified,,,,,Ratio of kcat to Km for Trametes versicolor laccase,Other,22300888.0,
1165,714147,2,2,,103196138,289,Unspecified,,,600.0,Km,Activity of Trametes versicolor laccase by spectrophotometric analysis,Confirmatory,22300888.0,
1166,720504,1,1,,57264281,289,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1167,720508,1,1,,57264281,289,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1168,720509,1,1,,57264281,289,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1169,720511,1,1,,57264281,289,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1170,720516,2,1,,144209515,289,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1171,720516,2,1,,144210473,289,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1172,720538,1,2,,90341698,289,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
1173,720542,1,2,,57264281,289,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1174,720543,1,1,,57264281,289,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1175,720551,1,2,,57264281,289,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1176,720552,2,1,,144209515,289,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1177,720552,2,1,,144210473,289,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1178,720553,1,2,,57264281,289,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1179,720559,1,2,,90341698,289,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
1180,720572,1,2,,90341698,289,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
1181,720573,1,2,,90341698,289,Inactive,3063388.0,5071.0,20.5962,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
1182,720579,2,1,,57264281,289,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1183,720580,1,1,,57264281,289,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1184,720582,1,1,,57264281,289,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1185,720596,1,1,,57264281,289,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1186,720634,2,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1187,720634,2,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1188,720635,2,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1189,720635,2,1,,144210473,289,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1190,720636,1,1,,17389988,289,Inconclusive,20149576.0,4780.0,18.8336,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1191,720637,2,1,,144209515,289,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1192,720637,2,1,,144210473,289,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1193,720648,1,1,,57264281,289,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1194,720652,1,1,,17389988,289,Inconclusive,,,42.1632,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1195,720653,1,1,,17389988,289,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
1196,720659,1,1,,17389988,289,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
1197,720674,2,2,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1198,720674,2,2,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1199,720675,2,2,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1200,720675,2,2,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1201,720678,2,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1202,720678,2,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1203,720679,2,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1204,720679,2,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1205,720680,2,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1206,720680,2,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1207,720681,2,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1208,720681,2,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1209,720682,2,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1210,720682,2,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1211,720683,2,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1212,720683,2,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1213,720684,2,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1214,720684,2,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1215,720685,2,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1216,720685,2,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1217,720686,2,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1218,720686,2,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1219,720687,2,2,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1220,720687,2,2,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1221,720691,4,1,,144209515,289,Inconclusive,311348376.0,2908.0,31.2702,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1222,720691,4,1,,144210473,289,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1223,720692,3,1,,144209515,289,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1224,720692,3,1,,144210473,289,Inconclusive,311348376.0,2908.0,43.6412,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1225,720693,3,1,,144209515,289,Inconclusive,,,22.1376,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1226,720693,3,1,,144210473,289,Inconclusive,,,54.941,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1227,720700,1,4,,57264281,289,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1228,720702,1,1,,57264281,289,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1229,720704,1,4,,57264281,289,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1230,720707,1,2,,57264281,289,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1231,720708,1,2,,57264281,289,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1232,720709,1,2,,57264281,289,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1233,720711,1,2,,57264281,289,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1234,720719,2,1,,144209515,289,Inconclusive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1235,720719,2,1,,144210473,289,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1236,720725,2,1,,144209515,289,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1237,720725,2,1,,144210473,289,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1238,721517,1,6,,103196138,289,Inactive,32129514.0,54583.0,,,Displacement of 2OG from catalytic domain of PHD2 (181 to 426) (unknown origin) Zn2 expressed in Escherichia coli at 150 uM,Other,23234607.0,
1239,743012,3,1,,144209515,289,Active,,,24.6338,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1240,743012,3,1,,144210473,289,Active,,,30.6379,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1241,743014,3,1,,144209515,289,Active,,,19.5673,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1242,743014,3,1,,144210473,289,Active,,,54.4827,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1243,743015,3,1,,144209515,289,Active,,,12.3461,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1244,743015,3,1,,144210473,289,Active,,,27.305999999999997,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1245,743033,3,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1246,743033,3,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1247,743035,2,1,,144209515,289,Inconclusive,124375976.0,367.0,3.5086,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1248,743035,2,1,,144210473,289,Inconclusive,124375976.0,367.0,3.8895,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1249,743036,2,1,,144209515,289,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1250,743036,2,1,,144210473,289,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1251,743040,3,1,,144209515,289,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1252,743040,3,1,,144210473,289,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1253,743041,3,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1254,743041,3,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1255,743042,3,1,,144209515,289,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1256,743042,3,1,,144210473,289,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1257,743053,2,1,,144209515,289,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1258,743053,2,1,,144210473,289,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1259,743054,2,1,,144209515,289,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1260,743054,2,1,,144210473,289,Inconclusive,124375976.0,367.0,54.4827,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1261,743063,2,1,,144209515,289,Inconclusive,124375976.0,367.0,3.00929,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1262,743063,2,1,,144210473,289,Inconclusive,124375976.0,367.0,3.60216,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1263,743064,3,1,,144209515,289,Active,,,17.4394,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1264,743064,3,1,,144210473,289,Active,,,15.3553,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1265,743065,3,1,,144209515,289,Active,399498506.0,24831.0,43.8058,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1266,743065,3,1,,144210473,289,Active,399498506.0,24831.0,43.2771,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1267,743066,3,1,,144209515,289,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1268,743066,3,1,,144210473,289,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1269,743067,2,1,,144209515,289,Inconclusive,399498506.0,24831.0,39.9514,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1270,743067,2,1,,144210473,289,Inconclusive,399498506.0,24831.0,35.7211,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1271,743069,2,1,,144209515,289,Inconclusive,348019627.0,2099.0,13.9679,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1272,743069,2,1,,144210473,289,Inconclusive,348019627.0,2099.0,21.8724,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1273,743074,2,1,,144209515,289,Inconclusive,,,44.1703,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1274,743074,2,1,,144210473,289,Inconclusive,,,43.6412,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1275,743075,2,1,,144209515,289,Active,348019627.0,2099.0,49.5599,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1276,743075,2,1,,144210473,289,Active,348019627.0,2099.0,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1277,743077,2,1,,144209515,289,Active,348019627.0,2099.0,52.5156,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1278,743077,2,1,,144210473,289,Active,348019627.0,2099.0,54.9544,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1279,743078,2,1,,144209515,289,Inconclusive,348019627.0,2099.0,15.6722,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1280,743078,2,1,,144210473,289,Inconclusive,348019627.0,2099.0,22.7281,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1281,743079,3,1,,144209515,289,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1282,743079,3,1,,144210473,289,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1283,743080,3,1,,144209515,289,Inactive,348019627.0,2099.0,69.4275,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1284,743080,3,1,,144210473,289,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1285,743081,3,1,,144209515,289,Inconclusive,,,69.4275,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1286,743081,3,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1287,743083,3,1,,144209515,289,Active,119597822.0,1588.0,27.6396,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1288,743083,3,1,,144210473,289,Inconclusive,119597822.0,1588.0,61.1306,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1289,743084,3,1,,144209515,289,Active,,,31.0121,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1290,743084,3,1,,144210473,289,Inconclusive,,,61.1306,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1291,743085,3,1,,144209515,289,Active,51095037.0,196.0,49.1509,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1292,743085,3,1,,144210473,289,Active,51095037.0,196.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1293,743086,3,1,,144209515,289,Inconclusive,,,55.1482,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1294,743086,3,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1295,743091,2,1,,144209515,289,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1296,743091,2,1,,144210473,289,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1297,743094,3,1,,144209515,289,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1298,743094,3,1,,144210473,289,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1299,743122,2,1,,144209515,289,Active,51095037.0,196.0,43.8058,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1300,743122,2,1,,144210473,289,Active,51095037.0,196.0,28.3743,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1301,743126,1,1,,57264281,289,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1302,743139,2,1,,144209515,289,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1303,743139,2,1,,144210473,289,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1304,743140,2,1,,144209515,289,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1305,743140,2,1,,144210473,289,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1306,743191,3,1,,144209515,289,Inconclusive,216409692.0,5468.0,24.8388,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1307,743191,3,1,,144210473,289,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1308,743194,3,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1309,743194,3,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1310,743199,2,1,,144209515,289,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1311,743199,2,1,,144210473,289,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1312,743202,4,1,,144209515,289,Inconclusive,20149576.0,4780.0,61.8773,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1313,743202,4,1,,144210473,289,Active,20149576.0,4780.0,30.6379,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1314,743203,3,1,,144209515,289,Inconclusive,,,43.8058,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1315,743203,3,1,,144210473,289,Inconclusive,,,61.1306,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1316,743205,1,1,,90341698,289,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
1317,743205,1,1,,90341698,289,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
1318,743206,1,1,,90341698,289,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
1319,743206,1,1,,90341698,289,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
1320,743207,1,1,,90341698,289,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
1321,743207,1,1,,90341698,289,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
1322,743209,3,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1323,743209,3,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1324,743210,4,1,,144209515,289,Inconclusive,4504517.0,3315.0,13.9679,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1325,743210,4,1,,144210473,289,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1326,743211,3,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1327,743211,3,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1328,743212,3,1,,144209515,289,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1329,743212,3,1,,144210473,289,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1330,743213,3,1,,144209515,289,Inconclusive,,,62.3922,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1331,743213,3,1,,144210473,289,Inconclusive,,,2.1872,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1332,743215,3,1,,144209515,289,Inconclusive,216409690.0,5467.0,17.5845,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1333,743215,3,1,,144210473,289,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1334,743217,3,1,,144209515,289,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1335,743217,3,1,,144210473,289,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1336,743218,3,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1337,743218,3,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1338,743219,3,1,,144209515,289,Active,20149576.0,4780.0,39.9514,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1339,743219,3,1,,144210473,289,Active,20149576.0,4780.0,20.4766,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1340,743220,3,1,,144209515,289,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1341,743220,3,1,,144210473,289,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1342,743221,3,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1343,743221,3,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1344,743222,3,1,,144209515,289,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1345,743222,3,1,,144210473,289,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1346,743223,3,1,,144209515,289,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1347,743223,3,1,,144210473,289,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1348,743224,3,1,,144209515,289,Inconclusive,,,55.6071,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1349,743224,3,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1350,743225,3,1,,144209515,289,Inconclusive,,,5.5607,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1351,743225,3,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1352,743226,2,1,,144209515,289,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1353,743226,2,1,,144210473,289,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1354,743227,2,1,,144209515,289,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1355,743227,2,1,,144210473,289,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1356,743228,3,1,,144209515,289,Inconclusive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1357,743228,3,1,,144210473,289,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1358,743238,1,1,,57264281,289,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
1359,743239,2,1,,144209515,289,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1360,743239,2,1,,144210473,289,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1361,743240,2,1,,144209515,289,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1362,743240,2,1,,144210473,289,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1363,743241,2,1,,144209515,289,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1364,743241,2,1,,144210473,289,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1365,743242,2,1,,144209515,289,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1366,743242,2,1,,144210473,289,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1367,743244,1,1,,90341698,289,Inconclusive,,,1.0,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1368,743247,1,2,,57264281,289,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1369,743255,1,1,,57264281,289,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
1370,743266,1,2,,57264281,289,Inactive,296080761.0,5745.0,44.6684,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
1371,743269,1,1,,57264281,289,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1372,743269,1,1,,57264281,289,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1373,743279,1,2,,57264281,289,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
1374,743288,1,1,,17389988,289,Inconclusive,,,6.3096,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
1375,743292,1,1,,17389988,289,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
1376,743397,1,1,,57264281,289,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1377,743398,1,1,,57264281,289,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1378,928031,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011127,Other,,
1379,928032,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011127,Other,,
1380,928033,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011127",Other,,
1381,928034,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011127,Other,,
1382,928035,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011127,Other,,
1383,928036,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011127,Other,,
1384,928037,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011127,Other,,
1385,928038,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011127,Other,,
1386,928039,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011127,Other,,
1387,928040,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011127,Other,,
1388,928041,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011127,Other,,
1389,928042,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011127,Other,,
1390,930684,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011127,Other,,
1391,930685,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011127,Other,,
1392,930686,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011127,Other,,
1393,930687,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011127,Other,,
1394,930688,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011127,Other,,
1395,930689,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011127,Other,,
1396,930690,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011127,Other,,
1397,930691,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011127,Other,,
1398,930692,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011127,Other,,
1399,930693,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011127,Other,,
1400,930694,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011127",Other,,
1401,930695,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011127,Other,,
1402,930696,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011127,Other,,
1403,930697,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011127,Other,,
1404,930698,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011127,Other,,
1405,930699,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011127,Other,,
1406,930700,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011127,Other,,
1407,930701,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011127,Other,,
1408,930702,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011127,Other,,
1409,930703,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011127,Other,,
1410,930704,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011127,Other,,
1411,930705,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011127,Other,,
1412,930706,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011127,Other,,
1413,930707,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011127,Other,,
1414,930708,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011127,Other,,
1415,930709,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011127,Other,,
1416,930710,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011127,Other,,
1417,930711,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011127,Other,,
1418,930712,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011127,Other,,
1419,930713,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011127,Other,,
1420,930714,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011127,Other,,
1421,930715,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011127,Other,,
1422,930716,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011127,Other,,
1423,930717,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011127,Other,,
1424,930718,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011127,Other,,
1425,930719,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011127,Other,,
1426,931346,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011127,Other,,
1427,931347,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011127,Other,,
1428,931348,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011127,Other,,
1429,931349,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011127,Other,,
1430,931350,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011127,Other,,
1431,931351,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011127,Other,,
1432,931352,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011127,Other,,
1433,931353,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011127",Other,,
1434,933370,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011127,Other,,
1435,933371,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011127,Other,,
1436,933372,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011127,Other,,
1437,933373,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011127,Other,,
1438,933374,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011127,Other,,
1439,933375,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011127,Other,,
1440,933376,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011127,Other,,
1441,933377,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011127,Other,,
1442,933378,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011127,Other,,
1443,933379,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011127,Other,,
1444,933380,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011127,Other,,
1445,933381,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011127,Other,,
1446,933382,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011127,Other,,
1447,933383,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011127,Other,,
1448,933384,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011127,Other,,
1449,933385,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011127,Other,,
1450,933386,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011127,Other,,
1451,933387,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011127,Other,,
1452,933388,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011127,Other,,
1453,933389,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011127",Other,,
1454,969706,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011127,Other,,
1455,969707,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011127,Other,,
1456,969708,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011127,Other,,
1457,969709,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011127,Other,,
1458,969710,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011127,Other,,
1459,969711,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011127,Other,,
1460,969712,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011127,Other,,
1461,969713,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011127,Other,,
1462,969714,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011127,Other,,
1463,969715,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011127,Other,,
1464,969716,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011127,Other,,
1465,969717,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011127,Other,,
1466,969718,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011127,Other,,
1467,969719,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011127,Other,,
1468,969720,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011127,Other,,
1469,969721,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011127,Other,,
1470,969722,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011127,Other,,
1471,969723,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011127,Other,,
1472,969724,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011127,Other,,
1473,969725,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011127,Other,,
1474,969726,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011127,Other,,
1475,969727,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011127,Other,,
1476,969728,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011127,Other,,
1477,969729,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011127,Other,,
1478,969730,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011127,Other,,
1479,969731,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011127,Other,,
1480,969732,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011127,Other,,
1481,969733,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011127,Other,,
1482,969734,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011127,Other,,
1483,969735,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011127,Other,,
1484,969736,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011127,Other,,
1485,969737,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011127,Other,,
1486,969738,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011127,Other,,
1487,969739,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011127,Other,,
1488,969740,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011127,Other,,
1489,969741,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011127,Other,,
1490,969742,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011127,Other,,
1491,969743,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011127,Other,,
1492,970374,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011127,Other,,
1493,972395,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011127,Other,,
1494,972396,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011127,Other,,
1495,972397,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011127,Other,,
1496,972398,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011127,Other,,
1497,972399,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011127,Other,,
1498,972400,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011127,Other,,
1499,972401,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011127,Other,,
1500,972402,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011127,Other,,
1501,972403,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011127,Other,,
1502,972404,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011127,Other,,
1503,972405,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011127,Other,,
1504,972406,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011127,Other,,
1505,972407,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011127,Other,,
1506,972408,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011127,Other,,
1507,972409,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011127,Other,,
1508,972410,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011127,Other,,
1509,972411,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011127,Other,,
1510,972412,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011127,Other,,
1511,972413,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011127,Other,,
1512,972414,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011127,Other,,
1513,972415,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011127,Other,,
1514,972416,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011127,Other,,
1515,972417,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011127,Other,,
1516,972418,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011127,Other,,
1517,972419,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011127,Other,,
1518,972420,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011127,Other,,
1519,972421,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011127,Other,,
1520,972422,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011127,Other,,
1521,972423,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011127,Other,,
1522,972424,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011127,Other,,
1523,972425,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011127,Other,,
1524,972426,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011127,Other,,
1525,972427,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011127,Other,,
1526,972428,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011127,Other,,
1527,972429,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011127,Other,,
1528,972430,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011127,Other,,
1529,973061,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011127,Other,,
1530,977608,3,1,,310263334,289,Active,,,4.3,IC50,Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB,Other,25053847.0,
1531,977611,3,1,,170482493,289,Active,295789296.0,,0.0004,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,20581821.0,
1532,977611,3,1,,310262862,289,Active,,,1500.0,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,25025339.0,
1533,1015581,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011127",Other,,
1534,1015599,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011127",Other,,
1535,1015600,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011127",Other,,
1536,1015601,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011127",Other,,
1537,1015602,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011127",Other,,
1538,1015603,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S011127",Other,,
1539,1015604,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S011127",Other,,
1540,1015605,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S011127",Other,,
1541,1015606,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S011127",Other,,
1542,1015607,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Spleen; Assay: Lymphoid Depletion; Study_ID: S011127,Other,,
1543,1015608,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Peritonitis; Study_ID: S011127,Other,,
1544,1015609,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Villus Tip Fusion; Study_ID: S011127,Other,,
1545,1015610,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S011127",Other,,
1546,1015611,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011127",Other,,
1547,1015612,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011127,Other,,
1548,1015613,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011127",Other,,
1549,1015614,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011127",Other,,
1550,1015615,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011127",Other,,
1551,1015616,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S011127",Other,,
1552,1015617,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S011127",Other,,
1553,1015618,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011127,Other,,
1554,1015619,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011127",Other,,
1555,1015620,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011127",Other,,
1556,1015621,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
1557,1015622,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011127",Other,,
1558,1015623,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011127",Other,,
1559,1015624,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011127",Other,,
1560,1015625,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S011127",Other,,
1561,1017450,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
1562,1017451,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011127",Other,,
1563,1017452,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011127",Other,,
1564,1017453,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011127",Other,,
1565,1017454,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011127",Other,,
1566,1017455,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011127,Other,,
1567,1017456,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011127",Other,,
1568,1018041,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011127,Other,,
1569,1018042,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011127",Other,,
1570,1018043,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011127",Other,,
1571,1018044,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011127",Other,,
1572,1018045,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011127",Other,,
1573,1018046,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011127",Other,,
1574,1018047,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011127",Other,,
1575,1018048,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011127",Other,,
1576,1018049,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011127",Other,,
1577,1018050,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011127",Other,,
1578,1018051,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
1579,1018052,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011127",Other,,
1580,1018053,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011127",Other,,
1581,1018054,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
1582,1018055,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
1583,1018056,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011127",Other,,
1584,1018057,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011127",Other,,
1585,1018058,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
1586,1018059,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011127",Other,,
1587,1018060,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011127",Other,,
1588,1018061,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
1589,1018062,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011127,Other,,
1590,1018063,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011127,Other,,
1591,1018064,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011127",Other,,
1592,1018065,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
1593,1018066,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
1594,1018067,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011127",Other,,
1595,1018068,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011127,Other,,
1596,1018069,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
1597,1018070,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
1598,1018071,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011127",Other,,
1599,1018072,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011127",Other,,
1600,1018073,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011127",Other,,
1601,1019944,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011127,Other,,
1602,1019945,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
1603,1020530,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011127",Other,,
1604,1020531,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011127",Other,,
1605,1020532,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
1606,1020533,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011127",Other,,
1607,1020534,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011127",Other,,
1608,1020535,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011127",Other,,
1609,1020536,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011127",Other,,
1610,1020537,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011127,Other,,
1611,1020538,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011127",Other,,
1612,1020539,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011127",Other,,
1613,1020540,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011127,Other,,
1614,1020541,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011127",Other,,
1615,1020542,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011127",Other,,
1616,1020543,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011127",Other,,
1617,1020544,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011127",Other,,
1618,1020545,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011127",Other,,
1619,1020546,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S011127,Other,,
1620,1020547,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011127",Other,,
1621,1020548,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011127",Other,,
1622,1020549,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011127",Other,,
1623,1020550,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011127",Other,,
1624,1020551,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011127",Other,,
1625,1020552,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S011127",Other,,
1626,1020553,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S011127",Other,,
1627,1020554,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S011127",Other,,
1628,1020555,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S011127",Other,,
1629,1020556,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Epithelial Atrophy; Study_ID: S011127,Other,,
1630,1020557,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011127,Other,,
1631,1020558,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011127",Other,,
1632,1020559,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011127,Other,,
1633,1020560,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011127",Other,,
1634,1020561,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011127",Other,,
1635,1020562,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011127",Other,,
1636,1020563,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011127",Other,,
1637,1020564,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011127",Other,,
1638,1020565,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011127",Other,,
1639,1020566,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011127",Other,,
1640,1020567,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011127",Other,,
1641,1023019,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S011127",Other,,
1642,1023020,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S011127,Other,,
1643,1023021,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
1644,1023022,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011127",Other,,
1645,1023023,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011127",Other,,
1646,1023024,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
1647,1023025,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
1648,1023026,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011127",Other,,
1649,1023027,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011127",Other,,
1650,1023028,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
1651,1023029,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011127",Other,,
1652,1023030,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011127",Other,,
1653,1023031,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
1654,1023032,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S011127",Other,,
1655,1023033,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S011127",Other,,
1656,1023034,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S011127",Other,,
1657,1023035,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Spleen; Assay: Extramedullary Hematopoiesis Increased; Study_ID: S011127,Other,,
1658,1023036,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011127,Other,,
1659,1023037,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011127,Other,,
1660,1023038,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011127",Other,,
1661,1023039,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
1662,1023040,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
1663,1023041,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011127",Other,,
1664,1023042,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S011127",Other,,
1665,1023043,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S011127",Other,,
1666,1023044,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S011127",Other,,
1667,1023045,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S011127",Other,,
1668,1023046,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011127,Other,,
1669,1023047,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S011127",Other,,
1670,1023048,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
1671,1023049,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
1672,1023050,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011127",Other,,
1673,1023051,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011127",Other,,
1674,1023052,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011127,Other,,
1675,1023053,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
1676,1023054,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011127",Other,,
1677,1023634,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S011127",Other,,
1678,1023635,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S011127",Other,,
1679,1023636,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011127",Other,,
1680,1023637,1,3,,103196138,289,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
1681,1029050,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Epithelial Atrophy; Study_ID: S011127,Other,,
1682,1029051,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Peritonitis; Study_ID: S011127,Other,,
1683,1029052,1,3,,103196138,289,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Intestine; Assay: Villus Tip Fusion; Study_ID: S011127,Other,,
1684,1053175,2,1,,178127152,289,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
1685,1053197,1,1,,57264281,289,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
1686,1059430,1,4,,103196138,289,Unspecified,123948.0,3620.0,,,Inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 using L-tryptophan as substrate at 1 mM after 1 hr relative to control,Other,24262887.0,
1687,1070384,1,1,,103196138,289,Active,,,,,Neuroprotective activity in mouse HT22 cells assessed as t-BOOH-induced toxicity at 40 uM preincubated for 3 hrs followed by t-BOOH induction measured after 9 hrs by MTT assay,Other,24245939.0,
1688,1070388,1,1,,103196138,289,Active,,,,,Neuroprotective activity in mouse HT22 cells assessed as reduction of t-BOOH-induced oxidative stress at 40 uM preincubated for 3 hrs followed by t-BOOH induction measured after 20 hrs by MTT assay,Other,24245939.0,
1689,1070389,1,1,,103196138,289,Active,,,,,Neuroprotective activity in mouse HT22 cells assessed as reduction of t-BOOH-induced oxidative stress at 40 uM preincubated for 3 hrs followed by t-BOOH induction measured for 20 hrs by time-resolved ECIS analysis,Other,24245939.0,
1690,1070390,1,1,,103196138,289,Unspecified,,,,,Cytotoxicity against mouse HT22 cells assessed as cell viability at 40 uM after 24 hrs by MTT assay,Other,24245939.0,
1691,1107734,1,1,,103196138,289,Inactive,,,,,Decrease in Botryosphaeria dothidea ligninolytic enzyme production assessed as pectinase activity using pectin as substrate at 1 mM measured at 28 degC after 4 days,Other,23731643.0,
1692,1107735,1,1,,103196138,289,Inactive,,,,,Decrease in Neofusicoccum ribis ligninolytic enzyme production assessed as pectinase activity using pectin as substrate measured at 28 degC after 4 days,Other,23731643.0,
1693,1107736,1,1,,103196138,289,Unspecified,,,,,Decrease in Lasiodiplodia theobromae ligninolytic enzyme production assessed as pectinase activity using pectin as substrate at 25 mM measured at 28 degC after 4 days,Other,23731643.0,
1694,1107741,1,1,,103196138,289,Unspecified,,,,,Decrease in Lasiodiplodia theobromae ligninolytic enzyme production assessed as laccase activity using ABTS as substrate at 1 mM measured at 28 degC after 4 days,Other,23731643.0,
1695,1107745,1,1,,103196138,289,Unspecified,,,,,Decrease in Lasiodiplodia theobromae mycelium biomass production measured at 28 degC after 4 days by gravimetric analysis,Other,23731643.0,
1696,1107746,1,1,,103196138,289,Unspecified,,,,,Decrease in Diplodia seriata (Schwein.) Shoemaker mycelium biomass production measured at 28 degC after 4 days by gravimetric analysis,Other,23731643.0,
1697,1107747,1,1,,103196138,289,Unspecified,,,,,Decrease in Neofusicoccum ribis mycelium biomass production at 25 mM measured at 28 degC after 4 days by gravimetric analysis,Other,23731643.0,
1698,1107749,1,1,,103196138,289,Active,,,,,Inhibition of Botryosphaeria dothidea mycelium growth at 20 mM measured at 28 degC after 4 days,Other,23731643.0,
1699,1107751,1,1,,103196138,289,Active,,,,,Inhibition of Diplodia seriata (Schwein.) Shoemaker mycelium growth at 15 mM measured at 28 degC after 4 days,Other,23731643.0,
1700,1107755,1,1,,103196138,289,Active,,,,,Inhibition of Neofusicoccum ribis mycelium growth at 20 mM measured at 28 degC after 4 days,Other,23731643.0,
1701,1107758,1,1,,103196138,289,Unspecified,,,,,Inhibition of Lasiodiplodia theobromae mycelium growth at 20 mM measured at 28 degC after 4 days,Other,23731643.0,
1702,1107760,1,1,,103196138,289,Unspecified,,,,,Inhibition of Lasiodiplodia theobromae mycelium growth measured at 28 degC after 4 days,Other,23731643.0,
1703,1107761,1,1,,103196138,289,Unspecified,,,,,Inhibition of Neofusicoccum ribis mycelium growth measured at 28 degC after 4 days,Other,23731643.0,
1704,1107762,1,1,,103196138,289,Unspecified,,,,,Inhibition of Diplodia seriata (Schwein.) Shoemaker mycelium growth measured at 28 degC after 4 days,Other,23731643.0,
1705,1107763,1,1,,103196138,289,Unspecified,,,,,Inhibition of Botryosphaeria dothidea mycelium growth measured at 28 degC after 4 days,Other,23731643.0,
1706,1110759,3,1,,103196138,289,Unspecified,,,,,Nematocidal activity against Caenorhabditis elegans assessed as mortality,Other,12147760.0,
1707,1113017,1,1,,103196138,289,Unspecified,,,,,Nematicidal activity against second-stage juveniles of Meloidogyne incognita (root-knot nematode) after 1 day by inverted microscopic analysis,Other,23379671.0,
1708,1113018,1,1,,103196138,289,Unspecified,,,,,Nematicidal activity against second-stage juveniles of Meloidogyne incognita (root-knot nematode) after 1 hr by inverted microscopic analysis,Other,23379671.0,
1709,1143539,1,1,,103196138,289,Unspecified,,,,,Antioxidant activity assessed as ABTS radical scavenging activity after 16 hrs by spectrophotometric analysis,Other,24842241.0,
1710,1143540,1,2,,103196138,289,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity by spectrophotometric analysis,Other,24842241.0,
1711,1143541,1,1,,103196138,289,Unspecified,,,,,Antioxidant activity assessed as galvinoxyl radical scavenging activity by spectrophotometric analysis,Other,24842241.0,
1712,1144294,1,1,,103196138,289,Active,,,,,Metal chelating activity of the compound assessed as Cu2+ complex formation at 1 x 10' -3 M by spectrometry,Other,1246044.0,
1713,1148422,2,1,,103196138,289,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,619150.0,
1714,1159509,1,1,,144209515,289,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1715,1159509,1,1,,144210473,289,Inconclusive,119626539.0,4790.0,0.8708,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1716,1159515,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1717,1159515,1,1,,144210473,289,Inconclusive,,,10.9622,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1718,1159516,1,1,,144209515,289,Inconclusive,119611100.0,22926.0,4.417,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1719,1159516,1,1,,144210473,289,Inconclusive,119611100.0,22926.0,9.77,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1720,1159517,1,1,,144209515,289,Inconclusive,,,7.0005,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1721,1159517,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1722,1159518,1,1,,144209515,289,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1723,1159518,1,1,,144210473,289,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1724,1159519,1,1,,144209515,289,Inconclusive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1725,1159519,1,1,,144210473,289,Inconclusive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1726,1159520,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1727,1159520,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1728,1159521,1,1,,144209515,289,Active,15928672.0,19885.0,8.7404,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1729,1159521,1,1,,144210473,289,Active,15928672.0,19885.0,27.305999999999997,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1730,1159523,1,1,,144209515,289,Active,15928672.0,19885.0,15.5429,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1731,1159523,1,1,,144210473,289,Active,15928672.0,19885.0,22.5385,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1732,1159524,1,1,,57264281,289,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1733,1159525,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1734,1159525,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1735,1159526,1,1,,144209515,289,Inconclusive,119627033.0,3725.0,31.2702,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1736,1159526,1,1,,144210473,289,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1737,1159527,1,1,,144209515,289,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1738,1159527,1,1,,144210473,289,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1739,1159528,1,1,,144209515,289,Inconclusive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1740,1159528,1,1,,144210473,289,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1741,1159529,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1742,1159529,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1743,1159531,1,1,,144209515,289,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1744,1159531,1,1,,144210473,289,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1745,1159551,1,1,,144209515,289,Inconclusive,,,4.3806,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1746,1159551,1,1,,144210473,289,Inconclusive,,,12.1972,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1747,1159552,1,1,,144209515,289,Inactive,325495463.0,5914.0,34.7962,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1748,1159552,1,1,,144210473,289,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1749,1159553,2,1,,144209515,289,Inactive,325495463.0,5914.0,69.4275,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1750,1159553,2,1,,144210473,289,Inconclusive,325495463.0,5914.0,48.5577,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1751,1159555,1,1,,144209515,289,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1752,1159555,1,1,,144210473,289,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1753,1159580,2,1,,268737962,289,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1754,1159583,2,1,,178127152,289,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
1755,1159606,1,1,,57264281,289,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
1756,1159607,2,1,,313041753,289,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1757,1224818,1,1,,312344405,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
1758,1224819,1,1,,312344405,289,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
1759,1224820,1,1,,312344405,289,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
1760,1224821,1,1,,312344405,289,Inactive,325495545.0,2101.0,8.4127,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
1761,1224822,1,1,,312344405,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
1762,1224823,1,1,,312344405,289,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
1763,1224834,3,1,,144209515,289,Active,,,43.8058,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1764,1224834,3,1,,144210473,289,Inconclusive,,,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1765,1224835,1,1,,144209515,289,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1766,1224835,1,1,,144210473,289,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1767,1224836,1,1,,144209515,289,Inconclusive,,,69.4275,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1768,1224836,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1769,1224837,1,1,,144209515,289,Inconclusive,,,43.8058,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1770,1224837,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1771,1224838,1,1,,144209515,289,Inactive,66775687.0,9970.0,55.1482,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1772,1224838,1,1,,144210473,289,Inactive,66775687.0,9970.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1773,1224839,1,1,,144209515,289,Inconclusive,66775687.0,9970.0,55.1482,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1774,1224839,1,1,,144210473,289,Inconclusive,66775687.0,9970.0,48.5577,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1775,1224840,3,1,,144209515,289,Inconclusive,,,34.7962,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1776,1224840,3,1,,144210473,289,Inconclusive,,,24.3365,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1777,1224841,3,1,,144209515,289,Inactive,325495545.0,2101.0,8.7404,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1778,1224841,3,1,,144210473,289,Inactive,325495545.0,2101.0,7.6959,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1779,1224842,3,1,,144209515,289,Active,325495545.0,2101.0,8.7404,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1780,1224842,3,1,,144210473,289,Active,325495545.0,2101.0,7.6959,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1781,1224843,1,1,,144209515,289,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1782,1224843,1,1,,144210473,289,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1783,1224844,1,1,,144209515,289,Inconclusive,,,22.1376,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1784,1224844,1,1,,144210473,289,Inconclusive,,,38.8952,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1785,1224845,1,1,,144209515,289,Inconclusive,344243002.0,100757539.0,40.5846,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1786,1224845,1,1,,144210473,289,Inconclusive,344243002.0,100757539.0,50.4772,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1787,1224846,1,1,,144209515,289,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1788,1224846,1,1,,144210473,289,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1789,1224847,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1790,1224847,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1791,1224848,3,1,,144209515,289,Active,325495545.0,2101.0,55.1482,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1792,1224848,3,1,,144210473,289,Active,325495545.0,2101.0,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1793,1224849,3,1,,144209515,289,Inactive,325495545.0,2101.0,55.1482,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1794,1224849,3,1,,144210473,289,Inactive,325495545.0,2101.0,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1795,1224857,2,1,,312344405,289,Inactive,,,19.9526,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1796,1224859,2,1,,90341698,289,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1797,1224865,1,2,,57264281,289,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
1798,1224867,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1799,1224867,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1800,1224868,1,1,,144209515,289,Active,,,39.3668,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1801,1224868,1,1,,144210473,289,Active,,,21.8724,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1802,1224869,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1803,1224869,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1804,1224870,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1805,1224870,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1806,1224871,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1807,1224871,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1808,1224872,1,1,,144209515,289,Active,,,55.6071,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1809,1224872,1,1,,144210473,289,Active,,,48.9662,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1810,1224873,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1811,1224873,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1812,1224874,1,1,,144209515,289,Active,,,35.0857,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1813,1224874,1,1,,144210473,289,Active,,,24.5412,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1814,1224875,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1815,1224875,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1816,1224876,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1817,1224876,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1818,1224877,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1819,1224877,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1820,1224878,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1821,1224878,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1822,1224879,1,1,,144209515,289,Inconclusive,,,24.8388,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1823,1224879,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1824,1224880,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1825,1224880,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1826,1224881,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1827,1224881,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1828,1224882,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1829,1224882,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1830,1224883,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1831,1224883,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1832,1224884,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1833,1224884,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1834,1224885,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1835,1224885,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1836,1224886,1,1,,144209515,289,Active,,,49.5599,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1837,1224886,1,1,,144210473,289,Active,,,24.5412,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1838,1224887,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1839,1224887,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1840,1224888,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1841,1224888,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1842,1224889,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1843,1224889,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1844,1224890,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1845,1224890,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1846,1224892,1,1,,144209515,289,Active,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1847,1224892,1,1,,144210473,289,Active,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1848,1224893,1,1,,144209515,289,Inconclusive,66775687.0,9970.0,60.7013,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1849,1224893,1,1,,144210473,289,Inconclusive,66775687.0,9970.0,56.6142,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1850,1224894,1,1,,144209515,289,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1851,1224894,1,1,,144210473,289,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1852,1224895,1,1,,144209515,289,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1853,1224895,1,1,,144210473,289,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1854,1224896,1,1,,144209515,289,Active,344243002.0,100757539.0,20.3405,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1855,1224896,1,1,,144210473,289,Active,344243002.0,100757539.0,28.3854,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1856,1224905,2,1,,121360966,289,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1857,1224905,2,1,,121360966,289,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1858,1238072,1,1,,103196138,289,Unspecified,115449.0,759.0,4003.0,Ki,Inhibition of human erythrocytes CA1 using 4-nitrophenylacetate as substrate by esterase assay,Confirmatory,26073005.0,
1859,1238073,1,1,,103196138,289,Active,115456.0,760.0,9.9,Ki,Inhibition of human erythrocytes CA2 using 4-nitrophenylacetate as substrate by esterase assay,Confirmatory,26073005.0,
1860,1238074,1,1,,103196138,289,Active,115449.0,759.0,,,Competitive inhibition of human erythrocytes CA1 using 4-nitrophenylacetate as substrate by Lineweaver-Burk plot analysis,Other,26073005.0,
1861,1257050,1,1,,103196138,289,Unspecified,115449.0,759.0,4003.0,Ki,Inhibition of human carbonic anhydrase 1 incubated for 15 mins prior to testing by stopped flow CO2 hydration assay,Confirmatory,26520662.0,
1862,1257051,1,1,,103196138,289,Active,115456.0,760.0,9.9,Ki,Inhibition of human carbonic anhydrase 2 incubated for 15 mins prior to testing by stopped flow CO2 hydration assay,Confirmatory,26520662.0,
1863,1257052,1,1,,103196138,289,Unspecified,83300925.0,768.0,115.0,Ki,Inhibition of human carbonic anhydrase 9 incubated for 15 mins prior to testing by stopped flow CO2 hydration assay,Confirmatory,26520662.0,
1864,1259241,1,1,,144209515,289,Inconclusive,,,49.1509,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1865,1259241,1,1,,144210473,289,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1866,1259242,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1867,1259242,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1868,1259243,1,1,,144209515,289,Inactive,124375976.0,367.0,27.6396,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1869,1259243,1,1,,144210473,289,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1870,1259244,1,1,,144209515,289,Active,348019627.0,2099.0,55.1482,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1871,1259244,1,1,,144210473,289,Inconclusive,348019627.0,2099.0,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1872,1259247,1,1,,144209515,289,Inconclusive,124375976.0,367.0,32.2254,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1873,1259247,1,1,,144210473,289,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1874,1259248,1,1,,144209515,289,Inconclusive,348019627.0,2099.0,55.1482,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1875,1259248,1,1,,144210473,289,Inconclusive,348019627.0,2099.0,61.1306,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1876,1259309,1,1,,178127152,289,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
1877,1259310,1,1,,332950580,289,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1878,1259311,1,1,,178127152,289,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
1879,1259313,1,1,,57264281,289,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
1880,1259318,1,1,,57264281,289,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
1881,1259354,1,1,,348443951,289,Inactive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
1882,1259364,1,1,,144209515,289,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1883,1259364,1,1,,144210473,289,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1884,1259365,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1885,1259365,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1886,1259366,1,1,,144209515,289,Active,,,9.8069,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1887,1259366,1,1,,144210473,289,Active,,,15.3553,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1888,1259367,1,1,,144209515,289,Active,,,6.1877,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1889,1259367,1,1,,144210473,289,Active,,,15.3553,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1890,1259368,1,1,,144209515,289,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1891,1259368,1,1,,144210473,289,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1892,1259369,1,1,,144209515,289,Active,109731339.0,2737.0,0.8740000000000001,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1893,1259369,1,1,,144210473,289,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1894,1259370,2,2,,124749594,289,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
1895,1259370,2,2,,124749594,289,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
1896,1259370,2,2,,124749594,289,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
1897,1259377,1,1,,144209515,289,Active,54288833.0,2100.0,21.9549,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1898,1259377,1,1,,144210473,289,Active,54288833.0,2100.0,24.3365,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1899,1259378,1,1,,144209515,289,Inconclusive,54288833.0,2100.0,43.8058,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1900,1259378,1,1,,144210473,289,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1901,1259379,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1902,1259379,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1903,1259380,1,1,,144209515,289,Inconclusive,,,27.6396,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1904,1259380,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1905,1259381,1,1,,144209515,289,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1906,1259381,1,1,,144210473,289,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1907,1259382,1,1,,144209515,289,Inconclusive,,,27.6396,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1908,1259382,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1909,1259383,1,1,,144209515,289,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1910,1259383,1,1,,144210473,289,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1911,1259384,1,1,,144209515,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1912,1259384,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1913,1259385,1,1,,144209515,289,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1914,1259385,1,1,,144210473,289,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1915,1259386,1,1,,144209515,289,Inconclusive,,,69.4275,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1916,1259386,1,1,,144210473,289,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1917,1259387,1,1,,144209515,289,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1918,1259387,1,1,,144210473,289,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1919,1259388,1,1,,144209515,289,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1920,1259388,1,1,,144210473,289,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1921,1259390,1,1,,144209515,289,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1922,1259390,1,1,,144210473,289,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1923,1259391,1,1,,144209515,289,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1924,1259391,1,1,,144210473,289,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1925,1259392,1,1,,144209515,289,Active,109731339.0,2737.0,1.34596,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1926,1259392,1,1,,144210473,289,Inconclusive,109731339.0,2737.0,1.9331200000000002,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1927,1259393,1,1,,144209515,289,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1928,1259393,1,1,,144210473,289,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1929,1259394,1,1,,144209515,289,Active,54288833.0,2100.0,23.2558,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1930,1259394,1,1,,144210473,289,Active,54288833.0,2100.0,26.278000000000002,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1931,1259395,1,1,,144209515,289,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1932,1259395,1,1,,144210473,289,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1933,1259396,1,1,,144209515,289,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1934,1259396,1,1,,144210473,289,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1935,1259401,1,1,,144209515,289,Inconclusive,325495545.0,2101.0,6.94275,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1936,1259401,1,1,,144210473,289,Inconclusive,325495545.0,2101.0,7.40614,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1937,1259402,1,1,,144209515,289,Active,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1938,1259402,1,1,,144210473,289,Active,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1939,1259403,1,1,,144209515,289,Inconclusive,325495545.0,2101.0,56.7586,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1940,1259403,1,1,,144210473,289,Inconclusive,325495545.0,2101.0,54.4827,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1941,1259404,1,1,,144209515,289,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1942,1259404,1,1,,144210473,289,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1943,1259407,1,1,,363898691,289,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1944,1259408,1,1,,363895370,289,Active,,,,,GENE-TOX mutagenicity studies,Other,,
1945,1259409,1,1,,363898691,289,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
1946,1259410,1,1,,363898691,289,Unspecified,,,,,CCRIS tumor promotion studies,Other,,
1947,1259411,1,1,,363898691,289,Active,,,,,CCRIS carcinogenicity studies,Other,,
1948,1259415,1,1,,57264281,289,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
1949,1259423,1,2,,354804222,289,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
